1
|
Lorenzi M, Resi MV, Bonanno L, Frega S, Dal Maso A, Ferro A, Guarneri V, Pasello G. Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients. Front Immunol 2024; 15:1308109. [PMID: 38348046 PMCID: PMC10859471 DOI: 10.3389/fimmu.2024.1308109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 01/12/2024] [Indexed: 02/15/2024] Open
Abstract
Extensive stage-Small-Cell Lung Cancer (ES-SCLC) is an aggressive cancer with dismal prognosis. The addition of immune-checkpoint inhibitors (ICIs) to platinum-based chemotherapy have been consistently demonstrated to improve outcomes and survival, becoming the new standard in first - line treatment of ES-SCLC patients. However, despite positive results reported in the pivotal trials, longer benefit appears evident only for a selected group of patients. Several predictive biomarkers have been studied so far but the prospective identification of patients more likely to experience better outcome seems to be challenging in SCLC. Indeed, classical immune predictive biomarkers as PD-L1 and tumor mutational burden (TMB) seem not to correlate with outcomes. Recently, a new molecular classification of SCLC based on differential expression of genes associated with specific clinical behaviors and therapeutic vulnerability have been presented suggesting a new field to be investigated. Despite the achievements, these studies focused mainly on inter-tumoral heterogeneity, limiting the exploration of intra-tumoral heterogeneity and cell to cell interactions. New analysis methods are ongoing in order to explore subtypes plasticity. Analysis on single biopsies cannot catch the whole genomic profile and dynamic change of disease over time and during treatment. Moreover, the availability of tissue for translational research is limited due to the low proportion of patients undergoing surgery. In this context, liquid biopsy is a promising tool to detect reliable predictive biomarkers. Here, we reviewed the current available data on predictive role of tissue and liquid biomarkers in ES-SCLC patients receiving ICIs. We assessed latest results in terms of predictive and prognostic value of gene expression profiling in SCLC. Finally, we explored the role of liquid biopsy as a tool to monitor SCLC patients over time.
Collapse
Affiliation(s)
- Martina Lorenzi
- Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy
| | - Maria Vittoria Resi
- Division of Medical Oncology 2, Veneto Institute of Oncology - IRCCS, Padova, Italy
- Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy
| | - Laura Bonanno
- Division of Medical Oncology 2, Veneto Institute of Oncology - IRCCS, Padova, Italy
| | - Stefano Frega
- Division of Medical Oncology 2, Veneto Institute of Oncology - IRCCS, Padova, Italy
| | - Alessandro Dal Maso
- Division of Medical Oncology 2, Veneto Institute of Oncology - IRCCS, Padova, Italy
| | - Alessandra Ferro
- Division of Medical Oncology 2, Veneto Institute of Oncology - IRCCS, Padova, Italy
| | - Valentina Guarneri
- Division of Medical Oncology 2, Veneto Institute of Oncology - IRCCS, Padova, Italy
- Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy
| | - Giulia Pasello
- Division of Medical Oncology 2, Veneto Institute of Oncology - IRCCS, Padova, Italy
- Department of Surgery, Oncology, and Gastroenterology, University of Padova, Padova, Italy
| |
Collapse
|
2
|
Gilyazova I, Gimalova G, Nizamova A, Galimova E, Ishbulatova E, Pavlov V, Khusnutdinova E. Non-Coding RNAs as Key Regulators in Lung Cancer. Int J Mol Sci 2023; 25:560. [PMID: 38203731 PMCID: PMC10778604 DOI: 10.3390/ijms25010560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Revised: 12/21/2023] [Accepted: 12/28/2023] [Indexed: 01/12/2024] Open
Abstract
For several decades, most lung cancer investigations have focused on the search for mutations in candidate genes; however, in the last decade, due to the fact that most of the human genome is occupied by sequences that do not code for proteins, much attention has been paid to non-coding RNAs (ncRNAs) that perform regulatory functions. In this review, we principally focused on recent studies of the function, regulatory mechanisms, and therapeutic potential of ncRNAs including microRNA (miRNA), long ncRNA (lncRNA), and circular RNA (circRNA) in different types of lung cancer.
Collapse
Affiliation(s)
- Irina Gilyazova
- Institute of Biochemistry and Genetics, Ufa Federal Research Center of Russian Academy of Sciences, 450054 Ufa, Russia
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia
| | - Galiya Gimalova
- Institute of Biochemistry and Genetics, Ufa Federal Research Center of Russian Academy of Sciences, 450054 Ufa, Russia
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia
| | - Aigul Nizamova
- Institute of Biochemistry and Genetics, Ufa Federal Research Center of Russian Academy of Sciences, 450054 Ufa, Russia
| | - Elmira Galimova
- Department of Pathological Physiology, Bashkir State Medical University, 450008 Ufa, Russia
| | - Ekaterina Ishbulatova
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia
| | - Valentin Pavlov
- Institute of Urology and Clinical Oncology, Department of Urology, Bashkir State Medical University, 450008 Ufa, Russia
| | - Elza Khusnutdinova
- Institute of Biochemistry and Genetics, Ufa Federal Research Center of Russian Academy of Sciences, 450054 Ufa, Russia
- Institute of Urology and Clinical Oncology, Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, 450008 Ufa, Russia
| |
Collapse
|
3
|
Guzeldemir-Akcakanat E, Sunnetci-Akkoyunlu D, Balta-Uysal VM, Özer T, Işik EB, Cine N. Differentially expressed miRNAs associated with generalized aggressive periodontitis. Clin Oral Investig 2023; 28:7. [PMID: 38123758 DOI: 10.1007/s00784-023-05404-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2023] [Accepted: 12/02/2023] [Indexed: 12/23/2023]
Abstract
OBJECTIVE This study aimed to investigate miRNA expression profiles in individuals with periodontitis which is a chronic inflammatory condition affecting the integrity of the periodontal attachment. miRNAs play a crucial role in gene regulation through various mechanisms, making them potential diagnostic markers and therapeutic targets for various diseases. MATERIALS AND METHODS A total of 25 individuals with aggressive periodontitis and 25 controls were included in the study. Gingival tissues were collected for miRNA isolation and cDNA synthesis. miRNAs associated with periodontitis, including hsa-miR-185-5p, hsa-miR-17, hs-miR-146a, hs-miR-146b, hs-miR-155, hs-miR-203, hs-miR-205, hs-miR-223, and hsa-miR-21-3p, were analyzed using a combination of miRTarBase database analysis and literature mining was performed. Real-time PCR was used to assess the expression patterns of the target miRNAs, and the data were analyzed using the REST program. RESULTS The study revealed upregulated expression levels of hsa-miR-223-3p, hsa-miR-203b-5p, hsa-miR-146a-5p, hsa-miR-146b-5p, and hsa-miR-155-5p in individuals with periodontitis. Conversely, downregulated expression was observed for hsa-miR-185-5p, hsa-miR-21-3p, and hsa-miR-17-3p. CONCLUSION The findings suggest significant differences in the expression of specific miRNAs associated with inflammation in periodontitis. MZB1 acts as a hormone-regulated adipokine/pro-inflammatory cytokine, driving chronic inflammation and influencing cellular expansion. Predominantly expressed in marginal zone and B1 B cells, specialized subsets that respond rapidly to infections, MZB1 impacts immune protein synthesis and immune cell maturation, notably targeting microRNA-185 to potentially impede T cell development. Further research is needed to elucidate the functional significance and potential implications of these miRNAs. CLINICAL RELEVANCE miRNAs regulate the expression of target genes by finely tuning protein expression levels. The current findings provide compelling evidence of notable variations in the expression levels of specific miRNAs associated with inflammation in individuals affected by periodontitis; hence, miRNAs hold promise as potential therapeutic targets for periodontitis.
Collapse
Affiliation(s)
- Esra Guzeldemir-Akcakanat
- Department of Periodontology, Faculty of Dentistry, Kocaeli University, 41190 Basiskele, Kocaeli, Turkey.
| | | | - V Merve Balta-Uysal
- Department of Periodontology, Faculty of Dentistry, Kocaeli University, 41190 Basiskele, Kocaeli, Turkey
| | - Tolgahan Özer
- Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
| | - Elif Büşra Işik
- Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
| | - Naci Cine
- Department of Medical Genetics, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
| |
Collapse
|
4
|
Pustylnyak VO, Alekseenok EY, Perevalova AM, Kozlov VV, Gulyaeva LF. Tumor suppressor PTEN regulation by tobacco smoke in lung squamous-cell carcinoma based on bioinformatics analysis. Heliyon 2023; 9:e19044. [PMID: 37609416 PMCID: PMC10440530 DOI: 10.1016/j.heliyon.2023.e19044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 08/01/2023] [Accepted: 08/08/2023] [Indexed: 08/24/2023] Open
Abstract
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), is a tumor suppressor inactivated in a variety of human cancers. PTEN alteration correlates with lung squamous-cell carcinoma (LUSC) histology. However, it is still unclear how tobacco smoke regulates PTEN in LUSC tissues. In this study, we used free online databases and online tools to analyze PTEN expression and the role of smoking on PTEN alteration in patients with LUSC. We validated bioinformatics data by performing RT-PCR analysis using LUSC patient samples. Our results showed a correlation between the downregulation of PTEN in LUSC tissues compared to normal tissues and smoking exposure. In silico results using online platforms suggest that hsa-mir-301a down-regulates PTEN expression level in smoking patients with LUSC. RT-PCR analysis demonstrated that the PTEN expression was significantly decreased, whereas expression of hsa-mir-301a was up-regulated in the smoker cohort of LUSC tissue compared to adjacent non-cancerous tissues. A significant negative correlation between PTEN and hsa-mir-301a levels was observed in tumour tissues in our cohort of LUSC patients. Our results suggest that the downregulation PTEN gene caused by tobacco smoke-mediated increase of hsa-mir-301a may play an important role in LUSC tumorigenesis.
Collapse
Affiliation(s)
- Vladimir O. Pustylnyak
- Novosibirsk State University, 630090, Novosibirsk, Russia
- Federal Research Center of Fundamental and Translational Medicine, 630117, Novosibirsk, Russia
| | - Efim Y. Alekseenok
- Federal Research Center of Fundamental and Translational Medicine, 630117, Novosibirsk, Russia
| | | | - Vadim V. Kozlov
- Federal Research Center of Fundamental and Translational Medicine, 630117, Novosibirsk, Russia
- Novosibirsk Regional Oncology Center, 630108, Novosibirsk, Russia
| | - Lyudmila F. Gulyaeva
- Novosibirsk State University, 630090, Novosibirsk, Russia
- Federal Research Center of Fundamental and Translational Medicine, 630117, Novosibirsk, Russia
| |
Collapse
|
5
|
Non-coding genome in small cell lung cancer between theoretical view and clinical applications. Semin Cancer Biol 2022; 86:237-250. [PMID: 35367369 DOI: 10.1016/j.semcancer.2022.03.024] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 03/22/2022] [Accepted: 03/26/2022] [Indexed: 01/27/2023]
Abstract
Small cell lung cancer (SCLC) is a highly aggressive cancer of the neuroendocrine system, characterized by poor differentiation, rapid growth, and poor overall survival (OS) of patients. Despite the recent advances in the treatment of SCLC recently, the 2-year survival rate of patients with the cancer is only 14-15%, occasioned by the acquired resistance to drugs and serious off-target effects. In humans, the coding region is only 2% of the total genome, and 20% of that is associated with human diseases. Beyond the coding genome are RNAs, promoters, enhancers, and other intricate elements. The non-coding regulatory regions, mainly the non-coding RNAs (ncRNAs), regulate numerous biological activities including cell proliferation, metastasis, and drug resistance. As such, they are potential diagnostic or prognostic biomarkers, and also potential therapeutic targets for SCLC. Therefore, understanding how non-coding elements regulate SCLC development and progression holds significant clinical implications. Herein, we summarized the recent discoveries on the relationship between the non-coding elements including long non-coding RNAs (lncRNA), microRNAs (miRNAs), circular RNA (circRNA), enhancers as well as promotors, and the pathogenesis of SCLC and their potential clinical applications.
Collapse
|
6
|
Identification of the Key miRNAs and Genes Associated with the Regulation of Non-Small Cell Lung Cancer: A Network-Based Approach. Genes (Basel) 2022; 13:genes13071174. [PMID: 35885958 PMCID: PMC9317345 DOI: 10.3390/genes13071174] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2022] [Revised: 06/18/2022] [Accepted: 06/20/2022] [Indexed: 11/26/2022] Open
Abstract
Lung cancer is the major cause of cancer-associated deaths across the world in both men and women. Lung cancer consists of two major clinicopathological categories, i.e., small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Lack of diagnosis of NSCLC at an early stage in addition to poor prognosis results in ineffective treatment, thus, biomarkers for appropriate diagnosis and exact prognosis of NSCLC need urgent attention. The proposed study aimed to reveal essential microRNAs (miRNAs) involved in the carcinogenesis of NSCLC that probably could act as potential biomarkers. The NSCLC-associated expression datasets revealed 12 differentially expressed miRNAs (DEMs). MiRNA-mRNA network identified key miRNAs and their associated genes, for which functional enrichment analysis was applied. Further, survival and validation analysis for key genes was performed and consequently transcription factors (TFs) were predicted. We obtained twelve miRNAs as common DEMs after assessment of all datasets. Further, four key miRNAs and nine key genes were extracted from significant modules based on the centrality approach. The key genes and miRNAs reported in our study might provide some information for potential biomarkers profitable to increased prognosis and diagnosis of lung cancer.
Collapse
|
7
|
Ahmadi A, Bayatiani MR, Seif F, Ansari J, Rashidi P, Moghadasi M, Etemadi M. Evaluation of Radiotherapy on miR-374 Gene Expression in Colorectal Cancer Patient Blood Samples. Rep Biochem Mol Biol 2022; 10:614-621. [PMID: 35291612 PMCID: PMC8903365 DOI: 10.52547/rbmb.10.4.614] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Accepted: 04/24/2021] [Indexed: 06/14/2023]
Abstract
BACKGROUND Current cancer treatments include surgery, radiotherapy, chemotherapy, and immunotherapy. Despite these treatments, a main issue in cancer treatment is early detection. microRNAs (miRNAs) can be used as markers to diagnose and treat cancers. This study investigated the effect of radiotherapy on miR-374 expression, and APC and GSK-3β, two of its target genes, in the WNT pathway, in peripheral blood samples from radiotherapy-treated colorectal cancer (CRC) patients. METHODS Peripheral blood was collected from 25 patients before and after radiotherapy. RNA was extracted from the blood and cDNA synthesized. miR-374, APC, and GSK-3β expression was determined by real-time polymerase chain reaction (RT-PCR) and the amplicons were sequenced. Finally, the data were statistically evaluated. RESULTS Quantitative RT-PCR revealed significant down-regulation of miR-374 (0.63-fold) and up-regulation of APC (1.12-fold) and GSK-3β (1.22-fold) in CRC patients after five weeks of radiotherapy. Sequencing of PCR-produced amplicons confirmed the conservation of mature and precursor sequences encoding miR-374. miR-374 expression changed with time after radiotherapy treatment and related tumor grading. Increased age and tumor grade positively correlated with decreased miR-374 expression. CONCLUSION miR-374 expression, and that of its two target genes, APC and GSK-3β, changed after radiotherapy. These genes can likely be used as diagnostic radiotherapy markers in CRC.
Collapse
Affiliation(s)
- Azam Ahmadi
- Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran.
| | - Mohammad Reza Bayatiani
- Department of Medical Physics and Radiotherapy, Arak University of Medical Sciences and Khansari Hospital, Arak, Iran.
| | - Fatemeh Seif
- Department of Medical Physics and Radiotherapy, Arak University of Medical Sciences and Khansari Hospital, Arak, Iran.
| | - Jamshid Ansari
- Department of Medical Physics and Radiotherapy, Arak University of Medical Sciences and Khansari Hospital, Arak, Iran.
| | - Parisa Rashidi
- Department of Medical Physics and Radiotherapy, Arak University of Medical Sciences and Khansari Hospital, Arak, Iran.
| | - Mona Moghadasi
- Students Research Committee, Arak University of Medical Sciences, Arak, Iran.
| | - Mobarakeh Etemadi
- Students Research Committee, Arak University of Medical Sciences, Arak, Iran.
| |
Collapse
|
8
|
Wang R, Li S, Wen W, Zhang J. Multi-Omics Analysis of the Effects of Smoking on Human Tumors. Front Mol Biosci 2021; 8:704910. [PMID: 34796198 PMCID: PMC8592943 DOI: 10.3389/fmolb.2021.704910] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 09/15/2021] [Indexed: 12/13/2022] Open
Abstract
Comprehensive studies on cancer patients with different smoking histories, including non-smokers, former smokers, and current smokers, remain elusive. Therefore, we conducted a multi-omics analysis to explore the effect of smoking history on cancer patients. Patients with smoking history were screened from The Cancer Genome Atlas database, and their multi-omics data and clinical information were downloaded. A total of 2,317 patients were included in this study, whereby current smokers presented the worst prognosis, followed by former smokers, while non-smokers showed the best prognosis. More importantly, smoking history was an independent prognosis factor. Patients with different smoking histories exhibited different immune content, and former smokers had the highest immune cells and tumor immune microenvironment. Smokers are under a higher incidence of genomic instability that can be reversed following smoking cessation in some changes. We also noted that smoking reduced the sensitivity of patients to chemotherapeutic drugs, whereas smoking cessation can reverse the situation. Competing endogenous RNA network revealed that mir-193b-3p, mir-301b, mir-205-5p, mir-132-3p, mir-212-3p, mir-1271-5p, and mir-137 may contribute significantly in tobacco-mediated tumor formation. We identified 11 methylation driver genes (including EIF5A2, GBP6, HGD, HS6ST1, ITGA5, NR2F2, PLS1, PPP1R18, PTHLH, SLC6A15, and YEATS2), and methylation modifications of some of these genes have not been reported to be associated with tumors. We constructed a 46-gene model that predicted overall survival with good predictive power. We next drew nomograms of each cancer type. Interestingly, calibration diagrams and concordance indexes are verified that the nomograms were highly accurate for the prognosis of patients. Meanwhile, we found that the 46-gene model has good applicability to the overall survival as well as to disease-specific survival and progression-free intervals. The results of this research provide new and valuable insights for the diagnosis, treatment, and follow-up of cancer patients with different smoking histories.
Collapse
Affiliation(s)
- Rui Wang
- Department of Hepatobiliary Surgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China
| | - Shanshan Li
- Department of Nursing, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China
| | - Wen Wen
- Department of Hepatobiliary Surgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China
| | - Jianquan Zhang
- Department of Hepatobiliary Surgery, Affiliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China
| |
Collapse
|
9
|
Saran U, Chandrasekaran B, Kolluru V, Tyagi A, Nguyen KD, Valadon CL, Shaheen SP, Kong M, Poddar T, Ankem MK, Damodaran C. Diagnostic molecular markers predicting aggressive potential in low-grade prostate cancer. Transl Res 2021; 231:92-101. [PMID: 33279680 DOI: 10.1016/j.trsl.2020.11.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 11/05/2020] [Accepted: 11/30/2020] [Indexed: 12/14/2022]
Abstract
Currently, clinicians rely on clinical nomograms to stratify progression risk at the time of diagnosis in patients with prostate cancer (CaP). However, these tools may not accurately distinguish aggressive potential in low-grade CaP. The current study determined the diagnostic potential of 3 molecular markers (ROCK1, RUNX3, and miR-301a) in terms of their ability to identify which low-grade tumors are likely to progress. Real-time PCR and immunohistochemical analysis were used to assess ROCK1, RUNX3, and miR-301a expression profiles in 118 serum and needle biopsy specimens. Expressions of ROCK1 and miR-301a were found to be significantly higher in Gleason 6 and 7 CaP as compared to BPH, while an inverse trend was observed with RUNX3. Further, incorporation of all 3 molecular markers significantly improved clinical nomograms' diagnostic accuracy and correlated with disease progression. Hence, in conclusion, the inclusion of these 3 molecular markers identified aggressive phenotype and predicted disease progression in low-grade CaP tumors at the time of diagnosis.
Collapse
Affiliation(s)
- Uttara Saran
- Department of Urology, University of Louisville, Louisville, KY
| | | | | | - Ashish Tyagi
- Department of Urology, University of Louisville, Louisville, KY
| | - Kristy D Nguyen
- Department of Urology, University of Louisville, Louisville, KY
| | | | - Saad P Shaheen
- Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY
| | | | | | - Murali K Ankem
- Department of Urology, University of Louisville, Louisville, KY
| | | |
Collapse
|
10
|
Pandey M, Mukhopadhyay A, Sharawat SK, Kumar S. Role of microRNAs in regulating cell proliferation, metastasis and chemoresistance and their applications as cancer biomarkers in small cell lung cancer. Biochim Biophys Acta Rev Cancer 2021; 1876:188552. [PMID: 33892053 DOI: 10.1016/j.bbcan.2021.188552] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Revised: 04/16/2021] [Accepted: 04/16/2021] [Indexed: 12/22/2022]
Abstract
Small cell lung cancer (SCLC), a smoking-related highly aggressive neuroendocrine cancer, is characterized by rapid cell proliferation, early metastatic dissemination, and early relapse due to chemoresistance to first-line platinum-doublet chemotherapy. Genomically, SCLC tumors show nearly universal loss of TP53 and RB1 tumor suppressor genes, while gene expression signature classifies them into 4 distinct subgroups based on the expression patterns of lineage transcription factors - ASCL1/ASH1, NEUROD1, YAP-1, and POU2F3. Due to the lack of targetable molecular alterations and clinically useful diagnostic, prognostic and predictive biomarker, there is insignificant progress in the therapeutic management of SCLC patients. Numerous studies have shown a significant involvement of non-coding RNAs in the regulation of cell proliferation, invasion and migration, apoptosis, metastasis, and chemoresistance in various human cancers. In this review, we comprehensively discuss the role of microRNAs (miRNAs) in regulating the aforementioned biological process in SCLC. For this, we searched the scientific literature and selected studies that have evaluated the role of miRNAs in the disease pathogenesis or as a cancer biomarker in SCLC. Our review suggests that several miRNAs are involved in the pathogenesis of SCLC mainly by regulating cell proliferation, metastasis, and chemoresistance. Few studies have also demonstrated the clinical utility of miRNAs in monitoring response to chemotherapy as well as in predicting survival outcomes. However, more in-depth mechanistic studies utilizing in vivo models and multicentric studies with larger patient cohorts are needed before the applications of miRNAs as therapeutic targets or as biomarkers are translated from the laboratory into clinics.
Collapse
Affiliation(s)
- Monu Pandey
- Dept. of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
| | - Abhirup Mukhopadhyay
- Dept. of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
| | - Surender K Sharawat
- Dept. of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
| | - Sachin Kumar
- Dept. of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
| |
Collapse
|
11
|
Zhong S, Golpon H, Zardo P, Borlak J. miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res 2021; 230:164-196. [PMID: 33253979 DOI: 10.1016/j.trsl.2020.11.012] [Citation(s) in RCA: 93] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2020] [Revised: 11/05/2020] [Accepted: 11/24/2020] [Indexed: 02/08/2023]
Abstract
Lung cancer (LC) is the leading cause of cancer-related death worldwide and miRNAs play a key role in LC development. To better diagnose LC and to predict drug treatment responses we evaluated 228 articles encompassing 16,697 patients and 12,582 healthy controls. Based on the criteria of ≥3 independent studies and a sensitivity and specificity of >0.8 we found blood-borne miR-20a, miR-10b, miR-150, and miR-223 to be excellent diagnostic biomarkers for non-small cell LC whereas miR-205 is specific for squamous cell carcinoma. The systematic review also revealed 38 commonly regulated miRNAs in tumor tissue and the circulation, thus enabling the prediction of histological subtypes of LC. Moreover, theranostic biomarker candidates with proven responsiveness to checkpoint inhibitor treatments were identified, notably miR-34a, miR-93, miR-106b, miR-181a, miR-193a-3p, and miR-375. Conversely, miR-103a-3p, miR-152, miR-152-3p, miR-15b, miR-16, miR-194, miR-34b, and miR-506 influence programmed cell death-ligand 1 and programmed cell death-1 receptor expression, therefore providing a rationale for the development of molecularly targeted therapies. Furthermore, miR-21, miR-25, miR-27b, miR-19b, miR-125b, miR-146a, and miR-210 predicted response to platinum-based treatments. We also highlight controversial reports on specific miRNAs. In conclusion, we report diagnostic miRNA biomarkers for in-depth clinical evaluation. Furthermore, in an effort to avoid unnecessary toxicity we propose predictive biomarkers. The biomarker candidates support personalized treatment decisions of LC patients and await their confirmation in randomized clinical trials.
Collapse
Affiliation(s)
- Shen Zhong
- Centre for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany
| | - Heiko Golpon
- Department of Pneumology, Hannover Medical School, Hannover, Germany
| | - Patrick Zardo
- Clinic for Cardiothoracic and Transplantation Surgery, Hannover Medical School, Hannover, Germany
| | - Jürgen Borlak
- Centre for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany.
| |
Collapse
|
12
|
Zhang YH, Jin M, Li J, Kong X. Identifying circulating miRNA biomarkers for early diagnosis and monitoring of lung cancer. Biochim Biophys Acta Mol Basis Dis 2020; 1866:165847. [DOI: 10.1016/j.bbadis.2020.165847] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 04/28/2020] [Accepted: 05/19/2020] [Indexed: 02/09/2023]
|
13
|
Wong JJM, Ginter PS, Tyryshkin K, Yang X, Nanayakkara J, Zhou Z, Tuschl T, Chen YT, Renwick N. Classifying Lung Neuroendocrine Neoplasms through MicroRNA Sequence Data Mining. Cancers (Basel) 2020; 12:E2653. [PMID: 32957587 PMCID: PMC7564332 DOI: 10.3390/cancers12092653] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 09/15/2020] [Indexed: 12/30/2022] Open
Abstract
Lung neuroendocrine neoplasms (NENs) can be challenging to classify due to subtle histologic differences between pathological types. MicroRNAs (miRNAs) are small RNA molecules that are valuable markers in many neoplastic diseases. To evaluate miRNAs as classificatory markers for lung NENs, we generated comprehensive miRNA expression profiles from 14 typical carcinoid (TC), 15 atypical carcinoid (AC), 11 small cell lung carcinoma (SCLC), and 15 large cell neuroendocrine carcinoma (LCNEC) samples, through barcoded small RNA sequencing. Following sequence annotation and data preprocessing, we randomly assigned these profiles to discovery and validation sets. Through high expression analyses, we found that miR-21 and -375 are abundant in all lung NENs, and that miR-21/miR-375 expression ratios are significantly lower in carcinoids (TC and AC) than in neuroendocrine carcinomas (NECs; SCLC and LCNEC). Subsequently, we ranked and selected miRNAs for use in miRNA-based classification, to discriminate carcinoids from NECs. Using miR-18a and -155 expression, our classifier discriminated these groups in discovery and validation sets, with 93% and 100% accuracy. We also identified miR-17, -103, and -127, and miR-301a, -106b, and -25, as candidate markers for discriminating TC from AC, and SCLC from LCNEC, respectively. However, these promising findings require external validation due to sample size.
Collapse
Affiliation(s)
- Justin J. M. Wong
- Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; (J.J.M.W.); (K.T.); (X.Y.); (J.N.); (Z.Z.)
| | - Paula S. Ginter
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA; (P.S.G.); (Y.-T.C.)
| | - Kathrin Tyryshkin
- Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; (J.J.M.W.); (K.T.); (X.Y.); (J.N.); (Z.Z.)
| | - Xiaojing Yang
- Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; (J.J.M.W.); (K.T.); (X.Y.); (J.N.); (Z.Z.)
| | - Jina Nanayakkara
- Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; (J.J.M.W.); (K.T.); (X.Y.); (J.N.); (Z.Z.)
| | - Zier Zhou
- Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; (J.J.M.W.); (K.T.); (X.Y.); (J.N.); (Z.Z.)
| | - Thomas Tuschl
- Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY 10065, USA;
| | - Yao-Tseng Chen
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY 10065, USA; (P.S.G.); (Y.-T.C.)
| | - Neil Renwick
- Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada; (J.J.M.W.); (K.T.); (X.Y.); (J.N.); (Z.Z.)
- Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY 10065, USA;
| |
Collapse
|
14
|
Wang W, Ma F, Zhang H. MicroRNA-374 is a potential diagnostic biomarker for atherosclerosis and regulates the proliferation and migration of vascular smooth muscle cells. Cardiovasc Diagn Ther 2020; 10:687-694. [PMID: 32968625 DOI: 10.21037/cdt-20-444] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Background The occurrence and development of atherosclerosis (AS) are closely related to the abnormality of vascular smooth muscle cells (VSMCs), and multiple microRNAs (miRNAs) have been reported to participate in the pathogenesis of AS. This study explored the expression and clinical value of miR-374 in the serum of AS patients, and analyzed its effect on the proliferation and migration of VSMCs. Methods The expression levels of miR-374 in the serum of 102 asymptomatic patients with AS and 89 healthy patients were detected by fluorescence quantitative PCR. The diagnostic value of miR-374 was evaluated through the receiver operating characteristic (ROC) curve. What's more, CCK-8 and Transwell assays were used to analyze the effects of miR-374 on the proliferation and migration of VSMCs. Results The expression level of miR-374 in the serum of AS patients was significantly higher than that of the control group. At the same time, the expression of miR-374 in AS patients was positively correlated with carotid intima-media thickness (CIMT). The area under the ROC curve is 0.824. Furthermore, overexpression of miR-374 significantly promoted the proliferation and migration of VSMCs, whereas reducing miR-374 inhibited the proliferation and migration of VSMCs. Conclusions The high expression of miR-374 may be a potential diagnostic marker for AS, and overexpression of miR-374 may play a role in AS by promoting the proliferation and migration of VSMCs.
Collapse
Affiliation(s)
- Weihong Wang
- Department of Healthcare, the Affiliated Hospital of Qingdao University, Qingdao, China
| | - Fenghua Ma
- Department of Healthcare, the Affiliated Hospital of Qingdao University, Qingdao, China
| | - Hongyan Zhang
- Department of Thoracic Surgery, the Affiliated Hospital of Qingdao University, Qingdao, China
| |
Collapse
|
15
|
Zhang L, Yang F, Yan Q. Candesartan ameliorates vascular smooth muscle cell proliferation via regulating miR-301b/STAT3 axis. Hum Cell 2020; 33:528-536. [PMID: 32170715 DOI: 10.1007/s13577-020-00333-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2019] [Accepted: 02/13/2020] [Indexed: 12/31/2022]
Abstract
Excessive vascular smooth muscle cell (VSMC) proliferation contributes to vascular remodeling and stroke during hypertension. Blockade of Angiotensin (AngII) type 1 receptor (AT1R) is shown to effectively attenuate VSMC proliferation and vascular remodeling, while the mechanisms underlying these protective effects are unclear. Here, we investigated whether the amelioration of VSMC proliferation mediated by candesartan, an AT1R blocker, could be associated with miRNA regulation. Based on the published data in rat aortic smooth muscle cells (RASMCs), we discovered that candesartan specifically reversed the AngII-induced decrease of miR-301b level in RASMCs and human aortic smooth muscle cells (HASMCs). Knockdown of miR-301b abolished candesartan-mediated inhibition of HASMC proliferation via promoting cell cycle transition. Computational analysis showed that miR-301b targets at 3'UTR of STAT3. MiR-301b upregulation inhibited the luciferase activity and protein expression of STAT3, whereas miR-301b knockdown increased STAT3 luciferase activity and expression. Furthermore, downregulation of STAT3 markedly abrogated the effects of miR-301b inhibition on candesartan-mediated HASMC proliferation, invasion, and migration. Collectively, this study suggests that miR-301b may be a novel molecular target of candesartan and provides a new understanding for the mechanisms underlying the cardiovascular effects of candesartan.
Collapse
Affiliation(s)
- Ling Zhang
- Department of Pharmacy, Xiantao First People's Hospital, No. 29 Mianzhou Road, Xiantao, 433000, Hubei, China.
| | - Fan Yang
- Department of Pharmacy, Xiantao First People's Hospital, No. 29 Mianzhou Road, Xiantao, 433000, Hubei, China
| | - Qiong Yan
- Department of Pharmacy, Huazhong University of Science and Technology Hospital, Wuhan, 430074, Hubei, China
| |
Collapse
|
16
|
Peng F, Xiong L, Xie X, Tang H, Huang R, Peng C. Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress Triple-Negative Breast Cancer Tumorigenesis and Development. Front Pharmacol 2020; 11:378. [PMID: 32296334 PMCID: PMC7137655 DOI: 10.3389/fphar.2020.00378] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Accepted: 03/12/2020] [Indexed: 12/12/2022] Open
Abstract
Triple-negative breast cancer (TNBC) is a subtype of breast cancer that accounts for the largest proportion of breast cancer-related deaths. Thus, it is imperative to search for novel drug candidates with potent anti-TNBC effects. Recent studies suggest that isoliquiritigenin (ISL) can significantly suppress the growth, migration, and invasion of breast cancer cells. We previously synthesized ISL derivatives and found that 3′,4′,5′,4″-tetramethoxychalcone (TMC) inhibits TNBC cell proliferation to a greater degree than ISL. The present study aimed to investigate the mechanisms underlying the anti-TNBC effects of TMC in vitro and in vivo. We show that TMC significantly inhibits the proliferative, migratory, and invasive abilities of MDA-MB-231 and BT549 cells. TMC induces apoptosis through the upregulation of Bax and downregulation of Bcl-2. PCR arrays demonstrate a significant decrease in miR-374a expression in TNBC cells after 24-h TMC treatment. MiR-374a is overexpressed in TNBC cells and has oncogenic properties. Real-time PCR analysis confirmed that TMC inhibits miR-374a in a dose-dependent manner, and luciferase assays confirmed that BAX is targeted by miR-374a. Further, we show that TMC increases Bax protein and mRNA levels by inhibiting miR-374a. TMC also attenuates TNBC tumor volumes and weights in vivo. These results demonstrate that TMC inhibits TNBC cell proliferation, foci formation, migration, invasion, and tumorigenesis, suggesting its potential to serve as a novel drug for treating TNBC through miR-374a repression.
Collapse
Affiliation(s)
- Fu Peng
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy, Sichuan University, Chengdu, China.,Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu, China.,Cardiovascular Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Liang Xiong
- Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Xiaofang Xie
- Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Hailin Tang
- Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China
| | - Ruizhen Huang
- Cardiovascular Department, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Cheng Peng
- Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|
17
|
Al-Sheikh YA, Ghneim HK, Alharbi KK, Aboul-Soud MAM. Screening for differentially‑expressed microRNA biomarkers in Saudi colorectal cancer patients by small RNA deep sequencing. Int J Mol Med 2019; 44:2027-2036. [PMID: 31638163 PMCID: PMC6844639 DOI: 10.3892/ijmm.2019.4362] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Accepted: 08/05/2019] [Indexed: 01/01/2023] Open
Abstract
Colorectal cancer (CRC) is mostly diagnosed at late stages leading to high mortality rates due to the scarcity of efficient screening approaches exhibiting high diagnostic utility. The current study employed a small-RNA deep-sequencing approach for screening microRNA (miRNA) differentially expressed genes (DEGs), and evaluating their potential as early diagnostic circulating biomarkers for CRC in clinical plasma and tissue samples from a Saudi patient population. The cohort followed a paired-study design composed of 20 CRC patients, providing plasma (P) and tissue (T) samples of CRC, and adjacent normal mucosa (CT). Also, control plasma (CP) samples were obtained from neoplasm-free healthy individuals to compare its miRNA levels with those in P samples. Illumina high-throughput (HiSeq 2000) sequencing was performed for the identification of known and novel miRNA genes that were differentially expressed in the plasma and tissues of CRC patients compared with CT and CP controls. While we identified only one known (hsa-miR-182-5p, significantly upregulated) and no novel DEGs at the most stringent significance level (P<0.001) in the P-CP comparison, we found 3 and none at P<0.01, 7 and 9 at P<0.05 level, respectively. In the T-CT comparison, the results revealed 24 known and 196 novel miRNA DEGs (P<0.001), 31 and 204 (P<0.01), 41 and 213 (P<0.05), respectively. Sequencing data were then analyzed by bioinformatics for potential diagnostic miRNAs. Network functional analysis for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway implicated two pathways rooted to signal transduction [Wnt and mitogen-activated protein kinase (MAPK)] that were enriched in CRC patients. Our results suggest that characterizing plasma and tissue profiles of CRC by deep sequencing may be a good strategy for identifying known and novel miRNAs and that the validated miRNAs described here may serve as potential CRC-associated biomarkers. Further research is necessary for determining their screen index values and diagnostic utility for the diagnosis of CRC.
Collapse
Affiliation(s)
- Yazeed A Al-Sheikh
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| | - Hazem K Ghneim
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| | - Khalid K Alharbi
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| | - Mourad A M Aboul-Soud
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| |
Collapse
|
18
|
Fan L, Wang Y, Huo W, Wang WH. MicroRNA‑301a‑3p overexpression promotes cell invasion and proliferation by targeting runt‑related transcription factor 3 in prostate cancer. Mol Med Rep 2019; 20:3755-3763. [PMID: 31485638 DOI: 10.3892/mmr.2019.10650] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2016] [Accepted: 04/06/2018] [Indexed: 11/06/2022] Open
Abstract
MicroRNAs (miRNAs) are known to serve a role in tumorigenic programs. The dysregulated expression of miR‑301a‑3p may affect the progression of various types of human cancer; however, the expression and the role of miR‑301a‑3p in prostate cancer are still unclear. The present study aimed to clarify the role and molecular mechanism of miR‑301a‑3p in prostate cancer. The results demonstrated that the expression of miR‑301a‑3p was significantly upregulated in human prostate cancer tissues and in several prostate cancer cell lines. In vitro overexpression of miR‑301a‑3p notably increased prostate cancer cell proliferation and invasion. Bioinformatics analysis revealed that runt‑related transcription factor 3 (RUNX3) may be a target of miR‑301a‑3p, which was confirmed by Dual‑luciferase reporter assay. Western blot analysis also demonstrated that miR‑301a‑3p regulated the protein expression levels of RUNX3. In addition, the results indicated that miR‑301a‑3p may regulate the Wnt signaling pathway, and rescue experiments indicated that RUNX3 contributed to the effects of miR‑301a‑3p on cell proliferation and invasion through Wnt signaling. In conclusion, these findings suggested that miR‑301a‑3p may promote prostate cancer cell invasion and proliferation by targeting RUNX3, and provided insight into understanding prostate cancer pathogenesis. miR‑301a‑3p may be a potential therapeutic candidate to treat prostate cancer.
Collapse
Affiliation(s)
- Li Fan
- Department of Urology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
| | - Yao Wang
- Department of Urology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
| | - Wei Huo
- Department of Urology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
| | - Wei-Hua Wang
- Department of Urology, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China
| |
Collapse
|
19
|
MicroRNA-374a promotes pancreatic cancer cell proliferation and epithelial to mesenchymal transition by targeting SRCIN1. Pathol Res Pract 2019; 215:152382. [DOI: 10.1016/j.prp.2019.03.011] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Revised: 02/12/2019] [Accepted: 03/04/2019] [Indexed: 12/20/2022]
|
20
|
Li X, Zhong M, Wang J, Wang L, Lin Z, Cao Z, Huang Z, Zhang F, Li Y, Liu M, Ma X. miR-301a promotes lung tumorigenesis by suppressing Runx3. Mol Cancer 2019; 18:99. [PMID: 31122259 PMCID: PMC6532219 DOI: 10.1186/s12943-019-1024-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Accepted: 05/02/2019] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Our previous report demonstrated that genetic ablation of miR-301a reduces Kras-driven lung tumorigenesis in mice. However, the impact of miR-301a on host anti-tumor immunity remains unexplored. Here we assessed the underlying molecular mechanisms of miR-301a in the tumor microenvironment. METHODS The differentially expressed genes were identified by using deep sequencing. The immune cell counts, and cytokines expression were analyzed by realtime PCR, immunohistochemistry and flow cytometry. The role of miR-301a/Runx3 in lung tumor was evaluated on cell growth, migration and invasion. The function of miR-301a/Runx3 in regulating tumor microenvironment and tumor metastasis were evaluated in Kras transgenic mice and B16/LLC1 syngeneic xenografts tumor models. RESULTS In this work, we identified 1166 up-regulated and 475 down-regulated differentially expressed genes in lung tumor tissues between KrasLA2 and miR-301a-/-; KrasLA2 mice. Immune response and cell cycle were major pathways involved in the protective role of miR-301a deletion in lung tumorigenesis. Overexpression of the miR-301a target, Runx3, was an early event identified in miR-301a-/-; KrasLA2 mice compared to WT-KrasLA2 mice. We found that miR-301a deletion enhanced CD8+ T cell accumulation and IFN-γ production in the tumor microenvironment and mediated antitumor immunity. Further studies revealed that miR-301a deficiency in the tumor microenvironment effectively reduced tumor metastasis by elevating Runx3 and recruiting CD8+ T cells, whereas miR-301a knockdown in tumor cells themselves restrained cell migration by elevating Runx3 expression. CONCLUSIONS Our findings further underscore that miR-301a facilitates tumor microenvironment antitumor immunity by Runx3 suppression in lung tumorigenesis.
Collapse
Affiliation(s)
- Xun Li
- Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of Mental Health and Cognitive Science, Center for Studies of Psychological Application, South China Normal University, Guangzhou, 510631 China
| | - Mingtian Zhong
- The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006 China
| | - Jiexuan Wang
- State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120 China
| | - Lei Wang
- Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of Mental Health and Cognitive Science, Center for Studies of Psychological Application, South China Normal University, Guangzhou, 510631 China
| | - Zhanwen Lin
- Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of Mental Health and Cognitive Science, Center for Studies of Psychological Application, South China Normal University, Guangzhou, 510631 China
| | - Zhi Cao
- The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006 China
| | - Zhujuan Huang
- The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006 China
| | - Fengxue Zhang
- The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006 China
| | - Yong Li
- Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH USA
| | - Ming Liu
- State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, 510120 China
| | - Xiaodong Ma
- Institute for Brain Research and Rehabilitation, Guangdong Key Laboratory of Mental Health and Cognitive Science, Center for Studies of Psychological Application, South China Normal University, Guangzhou, 510631 China
- The Research Center of Basic Integrative Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006 China
| |
Collapse
|
21
|
A novel label-free strategy for the ultrasensitive miRNA-182 detection based on MoS 2/Ti 3C 2 nanohybrids. Biosens Bioelectron 2019; 137:45-51. [PMID: 31078839 DOI: 10.1016/j.bios.2019.04.059] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 04/26/2019] [Accepted: 04/30/2019] [Indexed: 02/07/2023]
Abstract
MicroRNAs (miRNAs) are regarded as a large variety of cancer-related biomarkers, and they have attracted wide attentions in recent years. In this work, a novel label-free strategy for the ultrasensitive detection of miRNA-182 (a typical biomarker for lung cancer) based on MoS2/Ti3C2 nanohybrids was suggested. Firstly, modified glassy carbon electrode (GCE) with massive active sites and good electronic conductivity was prepared for biosensing. Then, based on this platform a descent signal in differential pulse voltammetry (DPV) peak current could be observed with the addition of probe RNA with negative charge. Thereafter, with the hybridization of target miRNA-182 with immobilized probe RNA and the swelling-induced breakage of Au-S bonds between RNA and the electrode surface, the characteristic DPV signals increase were found. In particular, this biosensing platform for special miRNAs possessed a good linear detection window in a range from 1 fM to 0.1 nM with a detection limit of 0.43 fM.
Collapse
|
22
|
Grange C, Brossa A, Bussolati B. Extracellular Vesicles and Carried miRNAs in the Progression of Renal Cell Carcinoma. Int J Mol Sci 2019; 20:ijms20081832. [PMID: 31013896 PMCID: PMC6514717 DOI: 10.3390/ijms20081832] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Revised: 04/10/2019] [Accepted: 04/11/2019] [Indexed: 12/17/2022] Open
Abstract
The formation and maintenance of renal cell carcinomas (RCC) involve many cell types, such as cancer stem and differentiated cells, endothelial cells, fibroblasts and immune cells. These all contribute to the creation of a favorable tumor microenvironment to promote tumor growth and metastasis. Extracellular vesicles (EVs) are considered to be efficient messengers that facilitate the exchange of information within the different tumor cell types. Indeed, tumor EVs display features of their originating cells and force recipient cells towards a pro-tumorigenic phenotype. This review summarizes the recent knowledge related to the biological role of EVs, shed by renal tumor cells and renal cancer stem cells in different aspects of RCC progression, such as angiogenesis, immune escape and tumor growth. Moreover, a specific role for renal cancer stem cell derived EVs is described in the formation of the pre-metastatic niche. We also highlight the tumor EV cargo, especially the oncogenic miRNAs, which are involved in these processes. Finally, the circulating miRNAs appear to be a promising source of biomarkers in RCC.
Collapse
Affiliation(s)
- Cristina Grange
- Department of Medical Sciences, University of Turin, via Nizza 52, 10126 Turin, Italy.
- Molecular Biotechnology Centre, University of Turin, via Nizza 52, 10126 Turin, Italy.
| | - Alessia Brossa
- Molecular Biotechnology Centre, University of Turin, via Nizza 52, 10126 Turin, Italy.
- Department of Molecular Biotechnology and Health Sciences, University of Turin, via Nizza 52, 10126 Turin, Italy.
| | - Benedetta Bussolati
- Molecular Biotechnology Centre, University of Turin, via Nizza 52, 10126 Turin, Italy.
- Department of Molecular Biotechnology and Health Sciences, University of Turin, via Nizza 52, 10126 Turin, Italy.
| |
Collapse
|
23
|
Bian H, Zhou Y, Zhou D, Zhang Y, Shang D, Qi J. The latest progress on miR-374 and its functional implications in physiological and pathological processes. J Cell Mol Med 2019; 23:3063-3076. [PMID: 30772950 PMCID: PMC6484333 DOI: 10.1111/jcmm.14219] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2018] [Revised: 01/10/2019] [Accepted: 01/23/2019] [Indexed: 12/17/2022] Open
Abstract
Non‐coding RNAs (ncRNAs) have been emerging players in cell development, differentiation, proliferation and apoptosis. Based on their differences in length and structure, they are subdivided into several categories including long non‐coding RNAs (lncRNAs >200nt), stable non‐coding RNAs (60‐300nt), microRNAs (miRs or miRNAs, 18‐24nt), circular RNAs, piwi‐interacting RNAs (26‐31nt) and small interfering RNAs (about 21nt). Therein, miRNAs not only directly regulate gene expression through pairing of nucleotide bases between the miRNA sequence and a specific mRNA that leads to the translational repression or degradation of the target mRNA, but also indirectly affect the function of downstream genes through interactions with lncRNAs and circRNAs. The latest studies have highlighted their importance in physiological and pathological processes. MiR‐374 family member are located at the X‐chromosome inactivation center. In recent years, numerous researches have uncovered that miR‐374 family members play an indispensable regulatory role, such as in reproductive disorders, cell growth and differentiation, calcium handling in the kidney, various cancers and epilepsy. In this review, we mainly focus on the role of miR‐374 family members in multiple physiological and pathological processes. More specifically, we also summarize their promising potential as novel prognostic biomarkers and therapeutic targets from bench to bedside.
Collapse
Affiliation(s)
- Hongjun Bian
- Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
| | - Yi Zhou
- Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
| | - Dawei Zhou
- Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
| | - Yongsheng Zhang
- Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
| | - Deya Shang
- Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
| | - Jianni Qi
- Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
| |
Collapse
|
24
|
Wang Z, Lu B, Sun L, Yan X, Xu J. Identification of candidate genes or microRNAs associated with the lymph node metastasis of SCLC. Cancer Cell Int 2018; 18:161. [PMID: 30364292 PMCID: PMC6194557 DOI: 10.1186/s12935-018-0653-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Accepted: 10/01/2018] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Small cell lung cancer (SCLC) is a highly malignant cancer, and over 70% of patients with SCLC present with the metastatic disease. We aimed to explore some novel differentially expressed genes (DEGs) or microRNAs (miRNAs) associated with the lymph node metastasis of SCLC. METHODS The DEGs between the metastasis and cancer groups were identified, and GO functional and KEGG pathway enrichment analyses for these DEGs were implemented. Subsequently, the protein-protein interaction network and subnetwork of module were constructed. Then the regulatory networks based on miRNAs, transcription factors (TFs) and target DEGs were constructed. Ultimately, the survival analysis for DEGs was performed to obtain the DEGs related to the survival of SCLC. RESULTS Here, 186 upregulated (e.g., GSR, HCP5) and 144 downregulated DEGs (e.g., MET, GRM8, and DACH1) were identified between the SCLC patients with lymph node metastasis and without lymph node metastasis. GRM8 was attracted to the G-protein coupled receptor signaling pathway. Besides, miR-126 was identified in the miRNAs-TFs-target regulatory network. GRM8 and DACH1 were all regulated by miR-126. In particular, GSR and HCP5 were correlated with survival of SCLC patients. CONCLUSION MiR-126, DACH1, GRM8, MET, GSR, and HCP5 were implicated in the lymph node metastasis process of SCLC.
Collapse
Affiliation(s)
- Zhonghao Wang
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of Harbin Medical University, No. 37, Yiyuan Street, Nangang District, Harbin, 150001 Heilongjiang China
| | - Bei Lu
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of Harbin Medical University, No. 37, Yiyuan Street, Nangang District, Harbin, 150001 Heilongjiang China
| | - Lixin Sun
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of Harbin Medical University, No. 37, Yiyuan Street, Nangang District, Harbin, 150001 Heilongjiang China
| | - Xi Yan
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of Harbin Medical University, No. 37, Yiyuan Street, Nangang District, Harbin, 150001 Heilongjiang China
| | - Jinzhi Xu
- Department of Thoracic Surgery, The Fourth Affiliated Hospital of Harbin Medical University, No. 37, Yiyuan Street, Nangang District, Harbin, 150001 Heilongjiang China
| |
Collapse
|
25
|
Gattolliat CH, Couvé S, Meurice G, Oréar C, Droin N, Chiquet M, Ferlicot S, Verkarre V, Vasiliu V, Molinié V, Méjean A, Dessen P, Giraud S, Bressac-De-Paillerets B, Gardie B, Tean Teh B, Richard S, Gad S. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease. Int J Oncol 2018; 53:1455-1468. [PMID: 30066860 PMCID: PMC6086628 DOI: 10.3892/ijo.2018.4490] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Accepted: 03/13/2018] [Indexed: 12/27/2022] Open
Abstract
Von Hippel-Lindau (VHL) disease is a rare auto-somal dominant syndrome that is the main cause of inherited clear-cell renal cell carcinoma (ccRCC), which generally occurs in the form of multiple recurrent synchronized tumors. Affected patients are carriers of a germline mutation in the VHL tumor suppressor gene. Somatic mutations of this gene are also found in sporadic ccRCC and numerous pan-genomic studies have reported a dysregulation of microRNA (miRNA) expression in these sporadic tumors. In order to investigate the molecular mechanisms underlying the pathogenesis of VHL-associated ccRCC, particularly in the context of multiple tumors, the present study characterized the mRNA and miRNA transcriptome through an integrative analysis compared with sporadic renal tumors. In the present study, two series of ccRCC samples were used. The first set consisted of several samples from different tumors occurring in the same patient, for two independent patients affected with VHL disease. The second set consisted of 12 VHL-associated tumors and 22 sporadic ccRCC tumors compared with a pool of normal renal tissue. For each sample series, an expression analysis of miRNAs and mRNAs was conducted using microarrays. The results indicated that multiple tumors within the kidney of a patient with VHL disease featured a similar pattern of miRNA and gene expression. In addition, the expression levels of miRNA were able to distinguish VHL-associated tumors from sporadic ccRCC, and it was identified that 103 miRNAs and 2,474 genes were differentially expressed in the ccRCC series compared with in normal renal tissue. The majority of dysregulated genes were implicated in 'immunity' and 'metabolism' pathways. Taken together, these results allow a better understanding of the occurrence of ccRCC in patients with VHL disease, by providing insights into dysregulated miRNA and mRNA. In the set of patients with VHL disease, there were few differences in miRNA and mRNA expression, thus indicating a similar molecular evolution of these synchronous tumors and suggesting that the same molecular mechanisms underlie the pathogenesis of these hereditary tumors.
Collapse
Affiliation(s)
| | - Sophie Couvé
- Oncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France
| | | | - Cédric Oréar
- Genomic Platform, Gustave Roussy, 94800 Villejuif, France
| | - Nathalie Droin
- Genomic Platform, Gustave Roussy, 94800 Villejuif, France
| | - Mathieu Chiquet
- Oncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France
| | - Sophie Ferlicot
- INSERM, UMR 1186, Gustave Roussy, Paris-Sud University, Paris-Saclay University, 94800 Villejuif, France
| | - Virginie Verkarre
- PREDIR INCa, Department of Urology, AP-HP, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France
| | - Viorel Vasiliu
- Department of Pathological Anatomy, Necker Hospital, 75015 Paris, France
| | - Vincent Molinié
- Department of Pathological Anatomy and Cytology, Saint Joseph Hospital, 75014 Paris, France
| | - Arnaud Méjean
- PREDIR INCa, Department of Urology, AP-HP, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France
| | | | - Sophie Giraud
- PREDIR INCa, Department of Urology, AP-HP, Bicêtre Hospital, 94270 Le Kremlin-Bicêtre, France
| | | | - Betty Gardie
- Oncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France
| | - Bin Tean Teh
- National Cancer Centre, Duke Graduate Medical School, Cancer Science Institute of Singapore, Institute of Molecular and Cellular Biology, Singapore 138673, Singapore
| | - Stéphane Richard
- Oncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France
| | - Sophie Gad
- Oncogenetics Laboratory, EPHE, PSL Research University, 75014 Paris, France
| |
Collapse
|
26
|
Zhang L, Dong B, Ren P, Ye H, Shi J, Qin J, Wang K, Wang P, Zhang J. Circulating plasma microRNAs in the detection of esophageal squamous cell carcinoma. Oncol Lett 2018; 16:3303-3318. [PMID: 30127929 DOI: 10.3892/ol.2018.8995] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2017] [Accepted: 11/02/2017] [Indexed: 12/13/2022] Open
Abstract
Circulating microRNAs (miRNAs/miRs) have been reported as diagnostic biomarkers for esophageal cancer (EC) diagnosis. However, contrasting results have been achieved in different studies. In the present study, a meta-analysis was performed, based on the systematic search of PubMed and Web of Science, to evaluate the diagnostic value of circulating miRNAs in the peripheral blood in EC. The top 5 most-studied miRNAs were selected for confirmation by reverse transcription quantitative-polymerase chain reaction using the blood plasma of 125 patients with esophageal squamous cell carcinoma (ESCC) and 125 healthy individuals from Henan, China. A total of 45 studies from 22 articles, regarding 33 miRNAs were considered in the meta-analysis. The pooled sensitivity and specificity were both 0.79 (95% confidence interval, 0.76-0.82 for both). Among the 5 miRNAs considered (miR-21, miR-223, miR-375, miR-25 and miR-100), miR-21 and miR-223 were significantly overexpressed whereas miR-375 expression was reduced in patients with ESCC compared with healthy individuals (all P<0.001). The areas under the curves (AUCs) were 0.80, 0.73, and 0.69 for miR-21, miR-223, and miR-375, respectively. The AUCs increased when discriminating between patients with early ESCC in stage 0-I and the non-invasive carcinoma stage Tis-T1 stage from controls. Thus, it was concluded that plasma miR-21, miR-223 and miR-375 may serve as non-invasive diagnostic biomarkers in patients with ESCC, especially early ESCC in stages 0-I and Tis-T1.
Collapse
Affiliation(s)
- Lu Zhang
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
| | - Bing Dong
- Department of Molecular Pathology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China
| | - Pengfei Ren
- Department of Molecular Pathology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China
| | - Hua Ye
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
| | - Jianxiang Shi
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
| | - Jiejie Qin
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
| | - Kaijuan Wang
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
| | - Peng Wang
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China
| | - Jianying Zhang
- Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan 450001, P.R. China.,Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
| |
Collapse
|
27
|
Uddin A, Chakraborty S. Role of miRNAs in lung cancer. J Cell Physiol 2018. [PMID: 29676470 DOI: 10.1002/jcp.26607] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2017] [Accepted: 03/16/2018] [Indexed: 12/18/2022]
Abstract
Lung cancer (LC) is the leading cause of cancer-related deaths all over the world, among both men and women, with an incidence of over 200,000 new cases per year coupled with a very high mortality rate. LC comprises of two major clinicopathological categories: small-cell (SCLC) and nonsmall-cell lung carcinoma (NSCLC). The microRNAs (miRNAs) are small noncoding RNAs, usually 18-25 nucleotides long, which repress protein translation through binding to complementary target mRNAs. The miRNAs regulate many biological processes including cell cycle regulation, cellular growth, proliferation, differentiation, apoptosis, metabolism, neuronal patterning, and aging. This review summarizes the role of miRNAs expression in LC. It also provides information about the miRNAs as biomarker and therapeutic target for lung cancer. Understanding the role of miRNAs in LC may provide insights into the diagnosis and treatment strategy for LC.
Collapse
Affiliation(s)
- Arif Uddin
- Department of Zoology, Moinul Hoque Choudhury Memorial Science College, Algapur, Hailakandi, Assam, India
| | | |
Collapse
|
28
|
Daugaard I, Venø MT, Yan Y, Kjeldsen TE, Lamy P, Hager H, Kjems J, Hansen LL. Small RNA sequencing reveals metastasis-related microRNAs in lung adenocarcinoma. Oncotarget 2018; 8:27047-27061. [PMID: 28460486 PMCID: PMC5432317 DOI: 10.18632/oncotarget.15968] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Accepted: 02/20/2017] [Indexed: 01/06/2023] Open
Abstract
The majority of lung cancer deaths are caused by metastatic disease. MicroRNAs (miRNAs) are posttranscriptional regulators of gene expression and miRNA dysregulation can contribute to metastatic progression. Here, small RNA sequencing was used to profile the miRNA and piwi-interacting RNA (piRNA) transcriptomes in relation to lung cancer metastasis. RNA-seq was performed using RNA extracted from formalin-fixed paraffin embedded (FFPE) lung adenocarcinomas (LAC) and brain metastases from 8 patients, and LACs from 8 patients without detectable metastatic disease. Impact on miRNA and piRNA transcriptomes was subtle with 9 miRNAs and 8 piRNAs demonstrating differential expression between metastasizing and non-metastasizing LACs. For piRNAs, decreased expression of piR-57125 was the most significantly associated with distant metastasis. Validation by RT-qPCR in a LAC cohort comprising 52 patients confirmed that decreased expression of miR-30a-3p and increased expression of miR-210-3p were significantly associated with the presence of distant metastases. miR-210-3p tumor cell specificity was evaluated by in situ hybridization and its biomarker potential was confirmed by ROC curve analysis (AUC = 0.839). Lastly, agreement between miRNA-seq and RT-qPCR for FFPE-derived RNA was evaluated and a high level of concordance was determined. In conclusion, this study has identified and validated metastasis-related miRNAs in LAC.
Collapse
Affiliation(s)
- Iben Daugaard
- Department of Biomedicine, Aarhus University, DK-8000 Aarhus C, Denmark.,Department of Molecular Biology and Genetics, Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark
| | - Morten T Venø
- Department of Molecular Biology and Genetics, Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark
| | - Yan Yan
- Department of Molecular Biology and Genetics, Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark
| | - Tina E Kjeldsen
- Department of Biomedicine, Aarhus University, DK-8000 Aarhus C, Denmark
| | - Philippe Lamy
- Department of Molecular Medicine, Aarhus University Hospital, DK-8200 Aarhus N, Denmark
| | - Henrik Hager
- Department of Pathology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.,Department of Clinical Pathology, Vejle Hospital, DK-7100 Vejle, Denmark
| | - Jørgen Kjems
- Department of Molecular Biology and Genetics, Interdisciplinary Nanoscience Center (iNANO), Aarhus University, DK-8000 Aarhus C, Denmark
| | - Lise Lotte Hansen
- Department of Biomedicine, Aarhus University, DK-8000 Aarhus C, Denmark
| |
Collapse
|
29
|
Liu J, Liu J, Shi L, Zhang F, Yu L, Yang X, Cai J. Preliminary study of microRNA-126 as a novel therapeutic target for primary hypertension. Int J Mol Med 2018; 41:1835-1844. [PMID: 29393351 PMCID: PMC5810200 DOI: 10.3892/ijmm.2018.3420] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 10/12/2017] [Indexed: 01/03/2023] Open
Abstract
The present study aimed to explore microRNA-126 (miR-126) as a novel therapeutic target for primary hypertension. The lentiviral vector containing human immunodeficiency virus 1 (HIV-1), the miR-126 gene knockdown viral vector (lenti-miR-126-KD), and control lentiviral vector (lenti-scramble-miR) were constructed. Spontaneously hypertensive rats were randomly divided into 4 groups, which received a high dose of lenti-miR-126-KD (1×108, n=5), low dose of lenti-miR-126-KD (1×107, n=6), scramble-miR (5×107, n=6), and PBS (n=6). Lentiviral vectors were injected into the tail vein. Data on the systolic blood pressure, diastolic pressure, mean arterial pressure, and heart rate were collected weekly. After 8 weeks of virus administration, the distribution of lentiviral vectors in different tissues was observed by fluorescence microscopy. Picric acid Sirius red and H&E staining were used to observe the target organ damage, and the ELISA kit was used to determine the serum nitric oxide (NO) content. The lentiviral vector was found to be constructed successfully. Eight weeks after the lentiviral vector injection, green fluorescent protein was observed in different tissues in each group. The blood pressure and heart rate were not significantly altered after lentiviral vector injection (P>0.05). No significant differences in the heart-to-body weight ratio among the four groups were observed (P=0.23). Picric acid Sirius red and H&E staining revealed that there was no significant difference in morphology among the four groups. No significant difference in the serum NO level among the four groups was noted (P=0.23). The miR-126 gene knockdown lentiviral vector was constructed successfully. No significant antihypertensive effect was observed by the knockdown of miR-126 for the treatment of primary hypertension. The target organs were not protected significantly after the treatment. The increased level of miR-126 expression in hypertensive patients may be due to a compensatory mechanism.
Collapse
Affiliation(s)
- Jia Liu
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Jiamei Liu
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Linying Shi
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Fan Zhang
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Liping Yu
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Xinchun Yang
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
| | - Jun Cai
- Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China
| |
Collapse
|
30
|
Zhao M, Xu P, Liu Z, Zhen Y, Chen Y, Liu Y, Fu Q, Deng X, Liang Z, Li Y, Lin X, Fang W. Dual roles of miR-374a by modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung cancer. Cell Death Dis 2018; 9:78. [PMID: 29362431 PMCID: PMC5833350 DOI: 10.1038/s41419-017-0103-7] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 10/23/2017] [Accepted: 10/26/2017] [Indexed: 12/16/2022]
Abstract
MiR-374a appears to play a complex role in non-small-cell lung cancer (NSCLC). Here, we demonstrate a dual role for miR-374a in NSCLC pathogenesis. The effects and modulatory mechanisms of miR-374a on cell growth, migration, invasion, and in vivo tumorigenesis and metastasis in nude mice were also analyzed. The expression of miR-374a was examined in NSCLC and non-cancerous lung tissues by quantitative real-time reverse transcription-PCR (qRT-PCR), and in situ hybridization, respectively. miR-374a directly targets CCND1 and inactivates PI3K/AKT and Ras-mediated cell cycle signalings, as well as epithelial–mesenchymal transition (EMT). This not only dramatically suppressed cell growth, migration, invasion,and metastasis, but also elevated A549 and pc-9 NSCLC cell sensitivity to cisplatin (DDP) while increasing survival time of tumor-bearing mice. Interestingly, miR-374a serves an inverse function in SPCA-1 and H1975 NSCLC cells by directly targeting PTEN to activate Wnt/β-catenin and Ras signalings and its downstream cascade signals. Surprisingly, transcription factor c-Jun bound to the promoter region of human miR-374a and suppressed miR-374a in A549 and pc-9 cells while inducing it in SPCA-1 and H1975 cells. Increased levels of miR-374a appeared to serve a protective role by targeting CCND1 in early-stage NSCLC (Stages I and II). Inversely, increased miR-374a was an unfavorable factor when targeting PTEN in more advanced staged NSCLC patients. Our studies are the first to demonstrate that miR-374a plays divergent roles in NSCLC pathogenesis at different stages of the disease and implicate the potential application of miR-374a targeting for cancer therapy.
Collapse
Affiliation(s)
- Mengyang Zhao
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.,Department of Oncology, The People's Hospital of Zhengzhou University, Zhengzhou, Henan, 450003, China
| | - Ping Xu
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.,Respiratory Department, Peking University Shenzhen Hospital, Shenzhen, 518034, China
| | - Zhen Liu
- Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences and Affiliated Cancer Hospital & Institute, Guangzhou Medical University, Guangzhou, 511436, China
| | - Yan Zhen
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Yiyu Chen
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Yiyi Liu
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Qiaofen Fu
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Xiaojie Deng
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Zixi Liang
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Yonghao Li
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Xian Lin
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China
| | - Weiyi Fang
- Cancer Center, Integrated Hospital of Traditional, Chinese Medicine, Southern Medical University, Guangzhou, 510315, China.
| |
Collapse
|
31
|
Peng F, Tang H, Liu P, Shen J, Guan X, Xie X, Gao J, Xiong L, Jia L, Chen J, Peng C. Isoliquiritigenin modulates miR-374a/PTEN/Akt axis to suppress breast cancer tumorigenesis and metastasis. Sci Rep 2017; 7:9022. [PMID: 28827662 PMCID: PMC5567123 DOI: 10.1038/s41598-017-08422-y] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Accepted: 07/10/2017] [Indexed: 01/15/2023] Open
Abstract
Breast cancer is one of the most frightful causes of death among females worldwide. Accumulating evidence attached the importance of microRNAs negative regulation to tumorigenesis in breast cancer, suggesting novel cancer therapies targeting microRNAs modulation. Recent studies demonstrated that isoliquiritigenin could inhibit breast cancer cells proliferation and migration, but the underlying mechanism is still limited. In this study, the anti-cancer effects as well as the detailed mechanisms of isoliquiritigenin were explored. The results proved that isoliquiritigenin could negatively regulate breast cancer growth through the induction of apoptosis. We also verified the anti-cancer effect of isoliquiritigenin on migration and invasion, and identified highly expressed miR-374a as one of the main microRNAs down-regulated by isoliquiritigenin treatment in breast cancer. Further study displayed that isoliquiritigenin increased PTEN expression through the decrease of miR-374a expression to inhibit the aberrant Akt signaling. Our findings suggest isoliquiritigenin as a novel anti-cancer candidate significantly regulating miR-374a/PTEN/Akt axis in microRNA-based breast cancer therapies.
Collapse
Affiliation(s)
- Fu Peng
- School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong.,Chengdu University of Traditional Chinese Medicine, Chengdu, China.,State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu, China
| | - Hailin Tang
- School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong.,Department of Breast Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
| | - Peng Liu
- Department of Breast Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
| | - Jiangang Shen
- School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | - Xinyuan Guan
- Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong
| | - Xiaofang Xie
- Chengdu University of Traditional Chinese Medicine, Chengdu, China.,State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu, China
| | - Jihai Gao
- Chengdu University of Traditional Chinese Medicine, Chengdu, China.,State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu, China
| | - Liang Xiong
- Chengdu University of Traditional Chinese Medicine, Chengdu, China.,State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu, China
| | - Lei Jia
- School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | - Jianping Chen
- School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong. .,Chengdu University of Traditional Chinese Medicine, Chengdu, China.
| | - Cheng Peng
- Chengdu University of Traditional Chinese Medicine, Chengdu, China. .,State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu, China.
| |
Collapse
|
32
|
Sato T, Shiba-Ishii A, Kim Y, Dai T, Husni RE, Hong J, Kano J, Sakashita S, Iijima T, Noguchi M. miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma. Cancer Sci 2017; 108:536-542. [PMID: 28012229 PMCID: PMC5378261 DOI: 10.1111/cas.13148] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 11/25/2016] [Accepted: 12/18/2016] [Indexed: 01/06/2023] Open
Abstract
Immunoglobulin (CD79a) binding protein 1 (IGBP1) is universally overexpressed in lung adenocarcinoma and exerts an anti‐apoptotic effect by binding to PP2Ac. However, the molecular mechanism of IGBP1 overexpression is still unclear. In the present study, we used a microRNA (miRNA) array and TargetScan Human software to detect IGBP1‐related miRNAs that regulate IGBP1 expression. The miRNA array analysis revealed more than 100 miRNAs that are dysregulated in early invasive adenocarcinoma. On the other hand, in silico analysis using TargetScan Human revealed 79 miRNAs that are associated with IGBP1 protein expression. Among the miRNAs selected by miRNA array analysis, six (miR‐34b, miR‐138, miR‐374a, miR‐374b, miR‐1909, miR‐3941) were also included among those selected by TargetScan analysis. Real‐time reverse transcription PCR (real‐time RT‐PCR) showed that the six microRNAs were downregulated in invasive adenocarcinoma (IGBP1+) relative to adjacent normal lung tissue (IGBP1−). Among these microRNAs, only miR‐34b and miR‐3941 depressed luciferase activity by targeting 3′UTR‐IGBP1 in the luciferase vector. We transfected miR‐34b and miR‐3941 into lung adenocarcinoma cell lines (A549, PC‐9), and both of them suppressed IGBP1 expression and cell proliferation. Moreover, the transfected miR‐34b and miR‐3941 induced apoptosis of a lung adenocarcinoma cell line, similarly to the effect of siIGBP1 RNA. As well as miR‐34b, we found that miR‐3941 targeted IGBP1 specifically and was able to exclusively downregulate IGBP1 expression. These findings indicate that suppression of miR‐3941 has an important role in the progression of lung adenocarcinoma at an early stage.
Collapse
Affiliation(s)
- Taiki Sato
- Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Aya Shiba-Ishii
- Department of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Yunjung Kim
- Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Tomoko Dai
- Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Ryan Edbert Husni
- Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - JeongMin Hong
- Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Junko Kano
- Department of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Shingo Sakashita
- Department of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| | - Tatsuo Iijima
- Department of Pathology, Ibaraki Prefectural Central Hospital, Kasama-shi, Ibaraki, Japan
| | - Masayuki Noguchi
- Department of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba-shi, Ibaraki, Japan
| |
Collapse
|
33
|
Mahmoodian Sani MR, Hashemzadeh-Chaleshtori M, Saidijam M, Jami MS, Ghasemi-Dehkordi P. MicroRNA-183 Family in Inner Ear: Hair Cell Development and Deafness. J Audiol Otol 2016; 20:131-138. [PMID: 27942598 PMCID: PMC5144812 DOI: 10.7874/jao.2016.20.3.131] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2015] [Revised: 07/09/2016] [Accepted: 09/06/2016] [Indexed: 01/19/2023] Open
Abstract
miRNAs are essential factors of an extensively conserved post-transcriptional process controlling gene expression at mRNA level. Varoius biological processes such as growth and differentiation are regulated by miRNAs. Web of Science and PubMed databases were searched using the Endnote software for the publications about the role miRNA-183 family in inner ear: hair cell development and deafness published from 2000 to 2016. A triplet of these miRNAs particularly the miR-183 family is highly expressed in vertebrate hair cells, as with some of the peripheral neurosensory cells. Point mutations in one member of this family, miR-96, underlie DFNA50 autosomal deafness in humans and lead to abnormal hair cell development and survival in mice. In zebrafish, overexpression of the miR-183 family induces extra and ectopic hair cells, while knockdown decreases the number of hair cell. The miR-183 family (miR-183, miR-96 and miR-182) is expressed abundantly in some types of sensory cell in the eye, nose and inner ear. In the inner ear, mechanosensory hair cells have a robust expression level. Despite much similarity of these miRs sequences, small differences lead to distinct targeting of messenger RNAs targets. In the near future, miRNAs are likely to be explored as potential therapeutic agents to repair or regenerate hair cells, cell reprogramming and regenerative medicine applications in animal models because they can simultaneously down-regulate dozens or even hundreds of transcripts.
Collapse
Affiliation(s)
- Mohammad Reza Mahmoodian Sani
- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Department of Genetics and Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
| | | | - Massoud Saidijam
- Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Department of Genetics and Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
| | - Mohammad-Saeid Jami
- Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Sharekord, Iran
| | - Payam Ghasemi-Dehkordi
- Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Sharekord, Iran
| |
Collapse
|
34
|
Wang X, Zhi X, Zhang Y, An G, Feng G. Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study. J Thorac Dis 2016; 8:1645-52. [PMID: 27499953 DOI: 10.21037/jtd.2016.06.21] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Lung cancer is a leading cause of cancer death worldwide. Early diagnosis is essential for improvements of prognosis and survival of the patients. Altered expressions in many cancer types including lung cancer and stable existence in plasma make microRNAs (miRNAs) a group of potentially useful biomarkers for clinical assessments of patients with lung cancer. In this study, we evaluate the potential values of miRNAs as plasma biomarkers for early diagnosis in non-small-cell lung cancers (NSCLC) by comparing with other typical plasma biomarkers. METHODS We analyzed the clinical and laboratory characteristics of 59 early-staged NSCLC (I-IIIA) patients and non-cancer controls by 1:1 matching age and gender from January 2012 to February 2014 in Xuanwu Hospital, Beijing, China. Peripheral blood samples from patients and controls before surgery were collected, and plasma was separated. Expression of ten miRNAs in the plasma of the patients and controls was detected by quantitative real-time polymerase chain reaction. Other typical markers, such as SCC, CEA, and CYFRA21-1 in plasma were also detected. The early diagnostic ability of miRNAs and other markers were evaluated by receiver-operating-characteristic (ROC) curve analysis. The sensitivity, specificity, and area under the curve were calculated for the cut-off value. RESULTS Plasma CYFRA21-1, miRNA-486 and miRNA-210 levels were significantly different in patients with NSCLC than those in controls (CYFRA21-1: 8.896±7.681 vs. 5.892±6.028, P=0.020; miR-486: 2.778±0.778 vs. 1.746±0.892, P<0.001; miR-210: 4.836±3.374 vs. 2.829±2.503, P<0.001). Area under ROC curve of CYFRA21-1, miR-486 and miR-210 were 0.624 (sensitivity: 0.576, specificity: 0.797), 0.848 (sensitivity: 0.831, specificity: 0.780) and 0.751 (sensitivity: 0.746, specificity: 0.746), respectively. The optimal cut-off value of CYFRA21-1, miRNA-486 and miRNA-210 were 6.595, 1.988 and 3.341, respectively to discriminate patients from controls. Plasma markers combined diagnosis ability had the highest sensitivity: 0.983, but the specificity was low. miR-486, miR-210 and CYFRA21-1 combined diagnosis ability was the highest, and the AUC was 0.924 (sensitivity: 0.847; specificity: 0.728). CONCLUSIONS The results suggest that miRNA-486 and miR-210 could be potential blood-based biomarkers for early diagnosis of NSCLC. miRNAs and other lab indexes may be combined to early diagnose NSCLC, which showed better ability of screening patients.
Collapse
Affiliation(s)
- Xin Wang
- Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China;; Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| | - Xiuyi Zhi
- Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| | - Yi Zhang
- Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
| | - Guangyu An
- Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
| | - Guosheng Feng
- Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China
| |
Collapse
|
35
|
Zhao X, Lu C, Chu W, Zhang Y, Zhang B, Zeng Q, Wang R, Li Z, Lv B, Liu J. microRNA-214 Governs Lung Cancer Growth and Metastasis by Targeting Carboxypeptidase-D. DNA Cell Biol 2016; 35:715-721. [PMID: 27494742 DOI: 10.1089/dna.2016.3398] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Lung cancer is one of the most malignant cancers with a high metastatic potential. The purpose of this study was to study the role and the underlying mechanism of miR-214 in lung cancer progression. The expression of miR-214 in normal lung and lung cancer tissue was analyzed by quantitative real-time PCR analysis. Furthermore, H1299 cells were infected with miR-214 lentivirus, and the effect of infection on cell viability and migration was analyzed. Carboxypeptidase-D (CPD), as a potential target of miR-214, was characterized in either normal lung or lung cancer tissues. The interaction of CPD expression with the tumor suppressing effect of miR-214 was characterized. We demonstrated that low miR-214 expression is a hallmark of lung cancer, especially high-grade and metastatic cancer. In vitro studies in H1299 cells confirmed that low miR-214 expression is associated with enhanced proliferation and migratory abilities. Similarly, CPD overexpression coincides with high-grade lung cancer and the CPD overexpression could reverse the inhibitory effects of miR-214. miR-214 is a tumor suppressor in lung cancer. miR-214 inhibits lung cancer progression by targeting CPD. The miR-214-CPD axis may be a therapeutic axis for lung cancer patients.
Collapse
Affiliation(s)
- Xiaojian Zhao
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Caiping Lu
- 2 Department of Endocrinology, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Weiwei Chu
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Yaxiao Zhang
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Bing Zhang
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Qiang Zeng
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Renfeng Wang
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Zhe Li
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Baolei Lv
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| | - Jiabao Liu
- 1 Department of Thoracic Surgery, The First Hospital of Shijiazhuang , Shijiazhuang, China
| |
Collapse
|
36
|
Damodaran C, Das TP, Papu John AMS, Suman S, Kolluru V, Morris TJ, Faber EN, Rai SN, Messer JC, Alatassi H, Ankem MK. miR-301a expression: A prognostic marker for prostate cancer. Urol Oncol 2016; 34:336.e13-20. [PMID: 27133223 PMCID: PMC4967401 DOI: 10.1016/j.urolonc.2016.03.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2016] [Revised: 03/10/2016] [Accepted: 03/14/2016] [Indexed: 01/26/2023]
Abstract
PURPOSE The diagnosis and treatment of prostate cancer (CaP) continues to be challenging, as prostate-specific antigen (PSA) appears to be overly sensitive and biopsy is the only reliable method for confirmation. Hence, the goal of the study is to identify a biomarker that could distinguish malignant cancer from benign prostatic hyperplasia (BPH) during the early diagnosis of the disease. MATERIALS AND METHODS A total of 75 formalin fixed paraffin embedded (FFPE) with matching controls, 4 paired metastatic tumors, 6 fresh tumor tissues and BPH (13 cases) with their clinical diagnosis were selected for this study. Prostate cancer cell lines and normal prostate epithelial cell lines were obtained from ATCC and subjected to phenotypic analysis. RESULTS We observed significant differential expression of miR-301a in CaP samples in comparison to BPH and adjacent benign samples. The overexpression of miR-301a activates the invasion/migration of CaP cells. In contrast, silencing miR-301a expression inhibited the colony-forming ability, adhesion, invasion and migration of CaP cells. Similarly, the overexpression of miR-301a increased cell motility in normal RWPE-1 prostate epithelial cells. Our results suggest that miR-301a is differentially expressed between BPH and CaP specimens and that the expression of miR-301a correlates with biochemical recurrence and/or metastasis in CaP patients. CONCLUSIONS The expression of miR-301a could be a potential marker for metastasis in CaP patients. Detecting miR-301a expression during diagnosis will avoid wait and watch timelines, thus preventing morbidity.
Collapse
Affiliation(s)
| | - Trinath P Das
- Department of Urology, University of Louisville, Louisville, KY
| | | | - Suman Suman
- Department of Urology, University of Louisville, Louisville, KY
| | | | | | - Erin N Faber
- Department of Pathology, University of Louisville, Louisville, KY
| | - Shesh N Rai
- Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY
| | - Jamie C Messer
- Department of Urology, University of Louisville, Louisville, KY
| | - Houda Alatassi
- Department of Pathology, University of Louisville, Louisville, KY
| | - Murali K Ankem
- Department of Urology, University of Louisville, Louisville, KY.
| |
Collapse
|
37
|
Wu D, Chen B, Cui F, He X, Wang W, Wang M. Hypoxia-induced microRNA-301b regulates apoptosis by targeting Bim in lung cancer. Cell Prolif 2016; 49:476-83. [PMID: 27352910 PMCID: PMC6495957 DOI: 10.1111/cpr.12264] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Accepted: 04/27/2016] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVES Worldwide, lung cancer accounts for the majority of cancer-related deaths. Aberrant expression of miRNAs has increasingly been reported to be associated with tumour progression. This study aimed to explore the role of miR-301b in regulating apoptosis in lung cancer. MATERIALS AND METHODS Expression of miR-301b was assessed by real-time PCR in cell lines, human patient tissues and cells treated under hypoxia and DMOG. Scramble siRNA, miR-301b inhibitor and miR-301b mimics were transfected into lung cancer cells to determine their effects on apoptosis. Additionally, a mouse xenograft model was used to explore functions of miR-301b on apoptosis, in vivo. Finally, relationships between Bim and miR-301b levels were explored by luciferase reporter assay and Western blotting. RESULTS We found that miR-301b was highly expressed in lung cancer tissues and cell lines. Expression of miR-301b was induced by hypoxia, and miR-301b suppressed expression of Bim by targeting its 3'UTR. Functionally, ectopic expression of miR-301b enhanced cell population growth, reduced apoptosis and reduced sensitivity of cells to chemotherapy. In the xenograft model, overexpression of miR-301b promoted tumour growth. Additionally, miR-301b and Bim expression were inversely correlated in clinical lung cancer samples. CONCLUSIONS This study provides new insights into the function of miRNA-301b in lung cancer and suggests that miRNA-301b could be a potential molecular target for chemotherapy.
Collapse
Affiliation(s)
- Duoguang Wu
- Department of OncologyNanfangHospital Southern Medical UniversityGuangzhouChina
- Department of Thoracic SurgeryThe Sun Yat‐Sen Memorial Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| | - Baishen Chen
- Department of OncologyNanfangHospital Southern Medical UniversityGuangzhouChina
- Department of Thoracic SurgeryThe Sun Yat‐Sen Memorial Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| | - Fei Cui
- Department of OncologyNanfangHospital Southern Medical UniversityGuangzhouChina
- Department of Thoracic SurgeryThe Sun Yat‐Sen Memorial Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| | - Xiaotian He
- Department of OncologyNanfangHospital Southern Medical UniversityGuangzhouChina
- Department of Thoracic SurgeryThe Sun Yat‐Sen Memorial Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| | - Wenjian Wang
- Department of OncologyNanfangHospital Southern Medical UniversityGuangzhouChina
- Department of Thoracic SurgeryThe Sun Yat‐Sen Memorial Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| | - Minghui Wang
- Department of OncologyNanfangHospital Southern Medical UniversityGuangzhouChina
- Department of Thoracic SurgeryThe Sun Yat‐Sen Memorial Hospital of Sun Yat‐Sen UniversityGuangzhouChina
| |
Collapse
|
38
|
Tagscherer KE, Fassl A, Sinkovic T, Richter J, Schecher S, Macher-Goeppinger S, Roth W. MicroRNA-210 induces apoptosis in colorectal cancer via induction of reactive oxygen. Cancer Cell Int 2016; 16:42. [PMID: 27293381 PMCID: PMC4901463 DOI: 10.1186/s12935-016-0321-6] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 06/02/2016] [Indexed: 12/14/2022] Open
Abstract
Background Deregulation of miRNA-210 is a common event in several types of cancer. However, increased expression levels in the cancer tissue have been associated with both poor and good prognosis of patients. Similarly, the function of miR-210 with regard to cell growth and apoptosis is still controversial. Methods Overexpression of miR-210 was performed in HCT116, SW480 and SW707 colorectal cancer (CRC) cell lines. Functional effects of a modulated miR-210 expression were analyzed with regard to proliferation, clonogenicity, cell cycle distribution, reactive oxygen species (ROS) generation, and apoptosis. Furthermore, quantitative real time (RT)-PCR and immunoblot analyses were performed to investigate signaling pathways affected by miR-210. Results We show that in CRC cells miR-210 inhibits clonogenicity and proliferation which was accompanied by an accumulation of cells in the G2/M phase of the cell cycle. Additionally, overexpression of miR-210 results in an increase of ROS generation. Moreover, miR-210 mediated the induction of apoptosis which was associated with an upregulation of pro-apoptotic Bim expression and enhanced processing of Caspase 2. Importantly, inhibition of ROS generation rescued cells from miR-210-induced apoptosis. Conclusions Taken together, miR-210 induces apoptosis in CRC cells via a ROS-dependent mechanism. Electronic supplementary material The online version of this article (doi:10.1186/s12935-016-0321-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Katrin E Tagscherer
- Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany ; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany ; Institute of Pathology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
| | - Anne Fassl
- Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany ; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215 USA ; Department of Genetics, Harvard Medical School, Boston, MA 02215 USA
| | - Tabea Sinkovic
- Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany ; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany
| | - Jutta Richter
- Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany ; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany ; Institute of Pathology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
| | - Sabrina Schecher
- Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany ; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany ; Institute of Pathology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
| | - Stephan Macher-Goeppinger
- Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany ; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany ; Institute of Pathology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
| | - Wilfried Roth
- Molecular Tumor-Pathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany ; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany ; Institute of Pathology, University Medical Center Mainz, Langenbeckstraße 1, 55131 Mainz, Germany
| |
Collapse
|
39
|
Zhen Y, Fang W, Zhao M, Luo R, Liu Y, Fu Q, Chen Y, Cheng C, Zhang Y, Liu Z. miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin. Oncogene 2016; 36:275-285. [PMID: 27270423 DOI: 10.1038/onc.2016.201] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Revised: 04/29/2016] [Accepted: 05/02/2016] [Indexed: 02/08/2023]
Abstract
miR-374a has been reported to function as an oncogene during tumor pathogenesis. In this study, miR-374a is observed to reduce nasopharyngeal carcinoma (NPC) cell proliferation, migration, invasion, metastasis and cisplatin (DDP) resistance in vitro and in vivo. Mechanistic analyses indicate that miR-374a directly targets CCND1 to inactivate pPI3K/pAKT/c-JUN forming a negative feedback loop, as well as suppressing downstream signals related to cell cycle progression and epithelial-mesenchymal transition (EMT). Interestingly, we also observed that miR-374a direct targeting of CCND1 is modulated by tumor suppressor PDCD4 via suppressing pPI3K/pAKT/c-JUN signaling. In clinical specimens, miR-374a was positively and negatively correlated with expression of PDCD4 and CCND1, respectively. Our studies are the first to demonstrate that the miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop induced by PDCD4 supresses NPC cell growth, metastasis and chemotherapy resistance.
Collapse
Affiliation(s)
- Y Zhen
- Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou, China.,Institute of Respiratory Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang, PR, China.,Cancer Research Institute, Southern Medical University, Guangzhou, PR, China
| | - W Fang
- Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou, China.,Cancer Research Institute, Southern Medical University, Guangzhou, PR, China
| | - M Zhao
- Cancer Research Institute, Southern Medical University, Guangzhou, PR, China
| | - R Luo
- Cancer Center, TCM-Integrated Hospital, Southern Medical University, Guangzhou, China
| | - Y Liu
- Cancer Research Institute, Southern Medical University, Guangzhou, PR, China
| | - Q Fu
- Cancer Research Institute, Southern Medical University, Guangzhou, PR, China
| | - Y Chen
- Cancer Research Institute, Southern Medical University, Guangzhou, PR, China
| | - C Cheng
- Cancer Research Institute, Southern Medical University, Guangzhou, PR, China
| | - Y Zhang
- Department of Pathology, School of Basic Medicine, Guangzhou Medical University, Guangzhou, PR, China
| | - Z Liu
- Cancer Research Institute, Southern Medical University, Guangzhou, PR, China.,Department of Pathology, School of Basic Medicine, Guangzhou Medical University, Guangzhou, PR, China
| |
Collapse
|
40
|
Kawano M, Tanaka K, Itonaga I, Iwasaki T, Tsumura H. MicroRNA-301a promotes cell proliferation via PTEN targeting in Ewing's sarcoma cells. Int J Oncol 2016; 48:1531-40. [PMID: 26846737 DOI: 10.3892/ijo.2016.3379] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2015] [Accepted: 01/13/2016] [Indexed: 12/25/2022] Open
Abstract
MicroRNAs (miRNAs) regulate cell proliferation and differentiation by affecting gene expression at the post-transcriptional level by binding to complementary sequences within mRNAs in cancer cells, indicating that miRNAs can function as tumor suppressors or oncogenes. Recent studies showed that dysregulation of miRNA expression was associated with increased tumorigenicity and poor prognosis in several types of cancers, including Ewing's sarcoma (ES). To explore possible oncogenic factors in ES, we conducted microarray-based investigation and profiled the changes in miRNA expression and their effects on downstream mRNAs in five ES cell lines and human mesenchymal stem cells (hMSCs). miR-301a was significantly upregulated, while the phosphatase and tensin homolog (PTEN) expression was significantly downregulated in all tested ES cells as compared to hMSCs. When anti-miR-301a was transfected into ES cell lines, PTEN expression was significantly enhanced, suggesting that PTEN might be a target of miR-301a in ES cells. The expression of protein kinase B (Akt), which is inversely correlated with PTEN expression, was significantly downregulated in anti-miR-301a-transfected cells. Additionally, the transfection of anti-miR-301a inhibited ES cell proliferation and cell cycle progression. Furthermore, downregulation of miR-301a in ES cells significantly suppressed tumor growth in vivo. Our results demonstrated the novel mechanism controlling PTEN expression via miR-301a in ES cells. Given that PTEN is a pivotal phosphatase factor that regulates cell cycle progression, apoptosis, and proliferation, these results might lead to development of new ES-related therapeutic targets.
Collapse
Affiliation(s)
- Masanori Kawano
- Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita 879-5593, Japan
| | - Kazuhiro Tanaka
- Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita 879-5593, Japan
| | - Ichiro Itonaga
- Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita 879-5593, Japan
| | - Tatsuya Iwasaki
- Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita 879-5593, Japan
| | - Hiroshi Tsumura
- Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita 879-5593, Japan
| |
Collapse
|
41
|
Greystoke A, Ayub M, Rothwell DG, Morris D, Burt D, Hodgkinson CL, Morrow CJ, Smith N, Aung K, Valle J, Carter L, Blackhall F, Dive C, Brady G. Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Mol Oncol 2016; 10:282-91. [PMID: 26654130 PMCID: PMC4750526 DOI: 10.1016/j.molonc.2015.10.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Accepted: 10/08/2015] [Indexed: 01/12/2023] Open
Abstract
Circulating miRNA stability suggests potential utility of miRNA based biomarkers to monitor tumor burden and/or progression, particularly in cancer types where serial biopsy is impractical. Assessment of miRNA specificity and sensitivity is challenging within the clinical setting. To address this, circulating miRNAs were examined in mice bearing human SCLC tumor xenografts and SCLC patient derived circulating tumor cell explant models (CDX). We identified 49 miRNAs using human TaqMan Low Density Arrays readily detectable in 10 μl tail vein plasma from mice carrying H526 SCLC xenografts that were low or undetectable in non-tumor bearing controls. Circulating miR-95 measured serially in mice bearing CDX was detected with tumor volumes as low as 10 mm(3) and faithfully reported subsequent tumor growth. Having established assay sensitivity in mouse models, we identified 26 miRNAs that were elevated in a stage dependent manner in a pilot study of plasma from SCLC patients (n = 16) compared to healthy controls (n = 11) that were also elevated in the mouse models. We selected a smaller panel of 10 previously reported miRNAs (miRs 95, 141, 200a, 200b, 200c, 210, 335#, 375, 429) that were consistently elevated in SCLC, some of which are reported to be elevated in other cancer types. Using a multiplex qPCR assay, elevated levels of miRNAs across the panel were also observed in a further 66 patients with non-small cell lung, colorectal or pancreatic cancers. The utility of this circulating miRNA panel as an early warning of tumor progression across several tumor types merits further evaluation in larger studies.
Collapse
Affiliation(s)
- Alastair Greystoke
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Mahmood Ayub
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Dominic G Rothwell
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Dan Morris
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Deborah Burt
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Cassandra L Hodgkinson
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Christopher J Morrow
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Nigel Smith
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Kyaw Aung
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK; The Christie NHS Foundation Trust, UK
| | - Juan Valle
- The Christie NHS Foundation Trust, UK; Institute of Cancer Sciences, University of Manchester, UK
| | - Louise Carter
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK; The Christie NHS Foundation Trust, UK
| | - Fiona Blackhall
- The Christie NHS Foundation Trust, UK; Institute of Cancer Sciences, University of Manchester, UK
| | - Caroline Dive
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK
| | - Ged Brady
- Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, UK.
| |
Collapse
|
42
|
Dong Y, Fu C, Guan H, Zhang Z, Zhou T, Li B. Prognostic significance of miR-126 in various cancers: a meta-analysis. Onco Targets Ther 2016; 9:2547-55. [PMID: 27217773 PMCID: PMC4853159 DOI: 10.2147/ott.s103481] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVE Recent studies have demonstrated that microRNA-126 (miR-126) might be a promising prognostic factor for cancer patients. This meta-analysis was conducted to assess the effectiveness of miR-126 as a prognostic biomarker for various cancers. METHODS The search of studies was performed by using PubMed and Embase until January 22, 2016. Pooled hazard ratio (HR) with 95% confidence interval (CI) for patients' survival was calculated. A fixed-effect or random-effects model was applied according to heterogeneity. The trim and fill method was used to adjust pooled HR. RESULTS In all 17 articles comprising of 2,437 participants were included in this meta-analysis. The results indicated that a high level of miR-126 played a favorable role in the overall survival (HR 0.70, 95% CI: 0.62-0.79, random-effects model), with a heterogeneity measure index of I (2)=63.2% (P<0.01). Subgroup analyses showed that pooled HR was more significant in patients with digestive system cancers (HR 0.70, 95% CI: 0.59-0.83, fixed-effects model) and respiratory system cancers (HR 0.71, 95% CI: 0.59-0.85, random-effects model). Owing to publication bias, HR was adjusted to 0.59 (0.463-0.752, P<0.01) by the trim and fill method. CONCLUSION miR-126 could be a promising biomarker for cancer prognosis prediction, especially in patients with digestive or respiratory system cancers.
Collapse
Affiliation(s)
- Yuanli Dong
- School of Medicine and Life Sciences, University of Jinan, Shandong Academy of Medical Sciences, Jinan, Shandong Province, People’s Republic of China
- Sixth Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, People’s Republic of China
| | - Chengrui Fu
- Sixth Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, People’s Republic of China
| | - Hui Guan
- Sixth Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, People’s Republic of China
| | - Zicheng Zhang
- Sixth Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, People’s Republic of China
| | - Tao Zhou
- Sixth Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, People’s Republic of China
| | - Baosheng Li
- Sixth Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan, Shandong Province, People’s Republic of China
- Correspondence: Baosheng Li, Sixth Department of Radiation Oncology, Shandong Cancer Hospital and Institute, 440 Jiyan Road, Jinan 250117, Shandong Province, People’s Republic of China, Tel +86 139 5416 8847, Fax +86 531 6762 6161, Email
| |
Collapse
|
43
|
Al-Sheikh YA, Ghneim HK, Softa KI, Al-Jobran AA, Al-Obeed O, Mohamed MAV, Abdulla M, Aboul-Soud MAM. Expression profiling of selected microRNA signatures in plasma and tissues of Saudi colorectal cancer patients by qPCR. Oncol Lett 2015; 11:1406-1412. [PMID: 26893751 PMCID: PMC4734292 DOI: 10.3892/ol.2015.4068] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Accepted: 12/30/2015] [Indexed: 01/13/2023] Open
Abstract
MicroRNAs (miRNAs or miRs) have been advocated as potentially robust and highly stable biomarkers of diverse disease conditions including cancer. The primary aim of this study was two-fold: i) to profile the expression levels of selected mature miRNA signature genes, such as miR-145, miR-195, miR-29 and miR-92, in a paired-study design of 20 colorectal cancer (CRC) tissues from patients versus adjacent neoplasm-free mucosal tissues employing reverse transcription-quantitative polymerase chain reaction; and ii) to examine their expression level in the plasma of the same CRC patients in relation to the age-matched plasma of healthy controls. Statistically significant (P<0.01) increases in miR-29 (2.5) and miR-92 (2.6) were observed in CRC tissues compared with adjacent neoplasm-free mucosal tissues. Profiling of CRC plasma samples showed that the expression levels of circulating miR-29 and miR-92 were significantly higher (P<0.01) than in the age-matched normal plasma. By contrast, miR-145 and miR-195 exhibited significant (P<0.05) decreases in their mean expression levels in CRC tissue samples in relation to the normal tissues. The mean expression levels of miR-145 and miR-195 were significantly lower (P<0.05) in CRC plasma than the healthy controls. Distinct stage-dependent changes in the expression level of the four miRNA gene profiles were observed between stages II and IV plasma of CRC patients relative to the control plasma. Taken together, the results clearly reflect a similar trend for the four miRNA expression levels in tissue and plasma as well as the positive correlation in the levels of miRNAs in tissues and plasma. These findings may be useful to clarify the molecular mechanisms underlying colorectal carcinogenesis and to underscore the potential of the investigated miRNAs as novel early diagnostic biomarkers of CRC.
Collapse
Affiliation(s)
- Yazeed A Al-Sheikh
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| | - Hazem K Ghneim
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| | - Khalil I Softa
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| | - Abdulrahman A Al-Jobran
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| | - Omar Al-Obeed
- Colorectal Research Center, Department of Surgery, College of Medicine, King Saud University, Riyadh 11472, Kingdom of Saudi Arabia
| | - Mansoor A V Mohamed
- Colorectal Research Center, Department of Surgery, College of Medicine, King Saud University, Riyadh 11472, Kingdom of Saudi Arabia
| | - Maha Abdulla
- Colorectal Research Center, Department of Surgery, College of Medicine, King Saud University, Riyadh 11472, Kingdom of Saudi Arabia
| | - Mourad A M Aboul-Soud
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh 11433, Kingdom of Saudi Arabia
| |
Collapse
|
44
|
Non-coding RNA: a new tool for the diagnosis, prognosis, and therapy of small cell lung cancer. J Thorac Oncol 2015; 10:28-37. [PMID: 25654726 DOI: 10.1097/jto.0000000000000394] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
In recent years, novel classes of noncoding RNAs (ncRNAs) have been discovered, which are implicated in diverse functional and regulatory activities. Growing evidence indicates that deregulated ncRNAs play crucial roles in the onset and progression of cancer, including small-cell lung cancer. In this review, we highlight nearly all of the findings regarding the roles and the possible mechanisms of ncRNAs as oncogenes or tumor suppressors in small-cell lung cancer. Furthermore, we discuss the possible role of ncRNAs as diagnostic biomarkers, their significant contribution to the prognosis, and their functions in regulating the response to therapy.
Collapse
|
45
|
Powrózek T, Krawczyk P, Kowalski DM, Winiarczyk K, Olszyna-Serementa M, Milanowski J. Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. Transl Res 2015; 166:315-23. [PMID: 26079400 DOI: 10.1016/j.trsl.2015.05.009] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2015] [Revised: 05/20/2015] [Accepted: 05/22/2015] [Indexed: 12/11/2022]
Abstract
Altered expression of microRNAs (miRNAs) is associated with the development and invasion of cancers by regulating post-transcriptionally gene function. Possibility of detection of miRNA expression in patients' plasma or serum makes them valuable biomarkers of different neoplasms. In the present study, we investigated the potential role of miR-944 and miR-3662 expression analysis as novel lung cancer biomarkers and their lung tumor specificity in plasma samples of 90 patients with lung cancer and 85 healthy individuals using quantitative reverse transcription-polymerase chain reaction analysis. Expression of miR-944 and miR-3662 was upregulated in patients with lung cancer in comparison with healthy individuals. Receiver operating curve analysis has presented diagnostic power of analysis of both miRNA expressions for detection of patients with I and II stages of non-small cell lung cancer with area under the curve (AUC) of 0.881. Moreover, miR-944 has shown diagnostic accuracy for operable squamous cell carcinoma detection (AUC = 0.982), whereas miR-3662 has shown the diagnostic accuracy for operable adenocarcinoma (AUC = 0.926). Higher stage of lung cancer correlated with higher miRNA expressions. Our results suggest that the profile of studied miRNAs could be further evaluated and considered as potential lung cancer biomarkers.
Collapse
Affiliation(s)
- Tomasz Powrózek
- Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland.
| | - Paweł Krawczyk
- Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland
| | - Dariusz M Kowalski
- Department of Lung and Chest Tumors Oncology Centre - Institute M. Sklodowska-Curie in Warsaw, Warsaw, Poland
| | - Kinga Winiarczyk
- Department of Lung and Chest Tumors Oncology Centre - Institute M. Sklodowska-Curie in Warsaw, Warsaw, Poland
| | - Marta Olszyna-Serementa
- Department of Lung and Chest Tumors Oncology Centre - Institute M. Sklodowska-Curie in Warsaw, Warsaw, Poland
| | - Janusz Milanowski
- Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, Poland
| |
Collapse
|
46
|
Rother S, Bartels M, Schweda AT, Resch K, Pallua N, Nourbakhsh M. NF‐κB‐repressing factor phosphorylation regulates transcription elongation
via
its interactions with 5'→3' exoribonuclease 2 and negative elongation factor. FASEB J 2015; 30:174-85. [DOI: 10.1096/fj.15-270256] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 08/31/2015] [Indexed: 12/22/2022]
Affiliation(s)
- Sascha Rother
- Institute of Pharmacology, Hannover Medical SchoolHannoverGermany
| | - Myriam Bartels
- Institute of Pharmacology, Hannover Medical SchoolHannoverGermany
| | | | - Klaus Resch
- Institute of Pharmacology, Hannover Medical SchoolHannoverGermany
| | - Norbert Pallua
- Department of Plastic and Reconstructive Surgery, Hand Surgery and Burn CenterRheinisch‐Westfälische Technische Hochschule (RWTH) Aachen University HospitalAachenGermany
| | - Mahtab Nourbakhsh
- Department of Plastic and Reconstructive Surgery, Hand Surgery and Burn CenterRheinisch‐Westfälische Technische Hochschule (RWTH) Aachen University HospitalAachenGermany
| |
Collapse
|
47
|
Abstract
Lung cancer is the most frequent cause of cancer-related death in Germany in men and women alike. While in the last decades a classification of epithelial lung tumors into non-small cell and small cell lung cancer was clearly sufficient from the therapeutic viewpoint, the dawn of the era of personalized medicine together with tremendous developments in the field of high throughput technologies have led to a molecular individualization of these tumors and, even more important, to a molecularly defined individualization of tumor therapy. This development resulted in the definition of a wide array of molecularly divergent tumor families. In this article we will give an overview on relevant molecular alterations in non-small cell lung cancers, comprising adenocarcinomas, squamous cell carcinomas and large cell carcinomas and also small cell carcinomas and carcinoids. Besides some similarities data gathered in the last few years specifically highlighted the immense diversity of molecular alterations that might underlie tumorigenesis of lung neoplasms. The knowledge on how to detect these alterations is of utmost importance in pathology, as treatment decisions are increasingly based on their presence or absence, putting molecular pathology in the central focus of the novel era of personalized medicine in oncology.
Collapse
|
48
|
Xiong Y, Kotian S, Zeiger MA, Zhang L, Kebebew E. miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer. PLoS One 2015; 10:e0130496. [PMID: 26244545 PMCID: PMC4526518 DOI: 10.1371/journal.pone.0130496] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Accepted: 05/19/2015] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Previous studies have shown that microRNAs are dysregulated in thyroid cancer and play important roles in the post-transcriptional regulation of target oncogenes and/or tumor suppressor genes. METHODOLOGY/PRINCIPAL FINDINGS We studied the function of miR-126-3p in thyroid cancer cells, and as a marker of disease aggressiveness. We found that miR-126-3p expression was significantly lower in larger tumors, in tumor samples with extrathyroidal invasion, and in higher risk group thyroid cancer in 496 papillary thyroid cancer samples from The Cancer Genome Atlas study cohort. In an independent sample set, lower miR-126-3p expression was observed in follicular thyroid cancers (which have capsular and angioinvasion) as compared to follicular adenomas. Mechanistically, ectopic overexpression of miR-126-3p significantly inhibited thyroid cancer cell proliferation, in vitro (p<0.01) and in vivo (p<0.01), colony formation (p<0.01), tumor spheroid formation (p<0.05), cellular migration (p<0.05), VEGF secretion and endothelial tube formation, and lung metastasis in vivo. We found 14 predicted target genes, which were significantly altered upon miR-126-3p transfection in thyroid cancer cells, and which are involved in cancer biology. Of these 14 genes, SLC7A5 and ADAM9 were confirmed to be inhibited by miR-126-3p overexpression and to be direct targets of miR-136-3p. CONCLUSIONS/SIGNIFICANCE To our knowledge, this is the first study to demonstrate that miR-126-3p has a tumor-suppressive function in thyroid cancer cells, and is associated with aggressive disease phenotype.
Collapse
Affiliation(s)
- Yin Xiong
- Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Shweta Kotian
- Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Martha A. Zeiger
- Department of Surgery, Johns Hopkins University, Baltimore, Maryland, United States of America
| | - Lisa Zhang
- Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Electron Kebebew
- Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
| |
Collapse
|
49
|
Looney AM, Walsh BH, Moloney G, Grenham S, Fagan A, O'Keeffe GW, Clarke G, Cryan JF, Dinan TG, Boylan GB, Murray DM. Downregulation of Umbilical Cord Blood Levels of miR-374a in Neonatal Hypoxic Ischemic Encephalopathy. J Pediatr 2015; 167:269-73.e2. [PMID: 26001314 DOI: 10.1016/j.jpeds.2015.04.060] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Revised: 03/17/2015] [Accepted: 04/22/2015] [Indexed: 12/16/2022]
Abstract
OBJECTIVE To investigate the expression profile of microRNA (miRNA) in umbilical cord blood from infants with hypoxic ischemic encephalopathy (HIE). STUDY DESIGN Full-term infants with perinatal asphyxia were identified under strict enrollment criteria. Degree of encephalopathy was defined using both continuous multichannel electroencephalogram in the first 24 hours of life and modified Sarnat score. Seventy infants (18 controls, 33 with perinatal asphyxia without HIE, and 19 infants with HIE [further graded as 13 mild, 2 moderate, and 4 severe]) were included in the study. MiRNA expression profiles were determined using a microarray assay and confirmed using quantitative real-time polymerase chain reaction. RESULTS Seventy miRNAs were differentially expressed between case and control groups. Of these hsa-miR-374a was the most significantly downregulated in infants with HIE vs controls. Validation of hsa-miR-374a expression using quantitative real-time polymerase chain reaction confirmed a significant reduction in expression among infants with HIE compared with those with perinatal asphyxia and healthy controls (mean relative quantification [SD] = 0.52 [0.37] vs 1.10 [1.52] vs 1.76 [1.69], P < .02). CONCLUSIONS We have shown a significant step-wise downregulation of hsa-miR-374a expression in cord blood of infants with perinatal asphyxia and subsequent HIE.
Collapse
Affiliation(s)
- Ann-Marie Looney
- Neonatal Brain Research Group, Irish Center for Fetal and Neonatal Translational Research, Department of Pediatrics and Child Health, Cork University Maternity Hospital, Wilton, Cork, Ireland
| | - Brian H Walsh
- Neonatal Brain Research Group, Irish Center for Fetal and Neonatal Translational Research, Department of Pediatrics and Child Health, Cork University Maternity Hospital, Wilton, Cork, Ireland
| | - Gerard Moloney
- Department of Anatomy and Neuroscience, Western Gateway Building, University College Cork, Cork, Ireland
| | - Sue Grenham
- Department of Anatomy and Neuroscience, Western Gateway Building, University College Cork, Cork, Ireland
| | - Ailis Fagan
- Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland
| | - Gerard W O'Keeffe
- Neonatal Brain Research Group, Irish Center for Fetal and Neonatal Translational Research, Department of Pediatrics and Child Health, Cork University Maternity Hospital, Wilton, Cork, Ireland; Department of Anatomy and Neuroscience, Western Gateway Building, University College Cork, Cork, Ireland
| | - Gerard Clarke
- Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland; Department of Psychiatry, Biosciences Institute, University College Cork, Cork, Ireland
| | - John F Cryan
- Department of Anatomy and Neuroscience, Western Gateway Building, University College Cork, Cork, Ireland; Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland
| | - Ted G Dinan
- Alimentary Pharmabiotic Center, University College Cork, Cork, Ireland; Department of Psychiatry, Biosciences Institute, University College Cork, Cork, Ireland
| | - Geraldine B Boylan
- Neonatal Brain Research Group, Irish Center for Fetal and Neonatal Translational Research, Department of Pediatrics and Child Health, Cork University Maternity Hospital, Wilton, Cork, Ireland
| | - Deirdre M Murray
- Neonatal Brain Research Group, Irish Center for Fetal and Neonatal Translational Research, Department of Pediatrics and Child Health, Cork University Maternity Hospital, Wilton, Cork, Ireland.
| |
Collapse
|
50
|
Song MK, Lee HS, Ryu JC. Integrated analysis of microRNA and mRNA expression profiles highlights aldehyde-induced inflammatory responses in cells relevant for lung toxicity. Toxicology 2015; 334:111-21. [DOI: 10.1016/j.tox.2015.06.007] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2015] [Revised: 06/08/2015] [Accepted: 06/09/2015] [Indexed: 12/12/2022]
|